glucose, (beta-d)-isomer has been researched along with Body Weight in 322 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (4.04) | 18.7374 |
| 1990's | 24 (7.45) | 18.2507 |
| 2000's | 29 (9.01) | 29.6817 |
| 2010's | 215 (66.77) | 24.3611 |
| 2020's | 41 (12.73) | 2.80 |
| Authors | Studies |
|---|---|
| Bramanti, P; Cuzzocrea, S; Di Paola, R; Esposito, E; Impellizzeri, D; Mazzon, E | 1 |
| Aloisi, C; Cuzzocrea, S; Galuppo, M; Italiano, D; Mazzon, E; Mondello, P; Mondello, S | 1 |
| Kang, JR; Li, F; Lu, JY; Tian, G; Wang, HW; Wang, XH; Yang, W; Yang, Y | 1 |
| Attaix, D; Combaret, L; Drost, MR; Hesselink, MK; Minnaard, R; Schaart, G; van Kranenburg, GP; Wagenmakers, AJ | 1 |
| Qian, X; Wang, S; Xu, B; Xue, Q; Yang, J; Yin, T; Zhu, Q | 1 |
| Helman, SI; Keefe, FB; Smith, JJ | 1 |
| Basamania, K; DuBose, DA; Maglione, L; Rowlands, J | 1 |
| Belghiti, J; Boivin, P; Fekete, F; Gautero, H; Goldfarb, G | 1 |
| Rooyackers, OE; Saris, WH; Soeters, PB; Wagenmakers, AJ | 1 |
| Ichikawa, T; Yano, T | 1 |
| Campbell, C; Daryani, R; Demling, R; Knox, J; Lalonde, C; Youn, YK | 1 |
| Dinarello, CA; Fantuzzi, G; Flavell, RA; Harding, MW; Ku, G; Kuida, K; Livingston, DJ; Sipe, JD | 1 |
| Corstens, FH; Goris, RJ; Hendriks, T; Knapen, MF; Nieuwenhuijzen, GA; Oyen, WJ | 1 |
| Dinarello, CA; Fantuzzi, G | 1 |
| Branch, RA; Carcillo, JA; Gillespie, DG; Jones, GS; Kochanek, PM; Korzekwa, KR; Kost, CK; Parise, RA; Whalen, MJ | 1 |
| Caputi, AP; Costantino, G; Cuzzocrea, S; Mazzon, E | 1 |
| Caputi, AP; Costantino, G; Cuzzocrea, S; Sottile, A; Teti, D; Zingarelli, B | 1 |
| de Man, BM; Goris, RJ; Hendriks, T; Jansen, MJ; van der Meer, JW | 1 |
| Babin-Chevaye, C; De Bandt, M; Driss, F; Grossin, M; Pasquier, C; Pincemail, J | 1 |
| Bahrami, S; Goris, RJ; Lieners, C; Redl, H; Schlag, G; van Bebber, IP | 1 |
| Goris, RJ; Schillings, PH; Speekenbrink, RG; van Bebber, IP | 1 |
| Bland, CE; Dallman, PR; Murakawa, H; Willis, WT | 1 |
| Furuya, E; Kasahara, T; Okazaki, M; Sakamoto, K | 1 |
| Benzoni, J; Deraedt, R; Vacher, J | 1 |
| Alcorn, J; Guo, Y; Mustafa, R; Purdy, SK; Reaney, MJT; Shen, J; Tse, TJ; Yang, X | 1 |
| Han, Y; He, SM; Wang, DD; Wang, TY; Wang, YM | 1 |
| Cheng, L; Fan, Y; Fu, Q; Lin, W; Liu, F; Wu, X; Zhang, X; Zhou, L | 1 |
| Hasebe, M; Ito, K; Kondo, Y; Satoh, S; Tamura, H; Terauchi, Y | 1 |
| Huh, Y; Kim, YS | 1 |
| Chen, HC; Yang, AY | 1 |
| Amevor, FK; Cui, Z; Deng, X; Du, X; Feng, J; Han, X; Jin, N; Kang, X; Li, D; Ning, Z; Shu, G; Tian, Y; Wang, X; Wang, Y; Zhang, Y; Zhao, X; Zhu, Q | 1 |
| Ahn, SH; Cho, Y; Choi, YJ; Hong, S; Kim, SH; Lee, E; Lee, YH; Seo, DH; Seo, S; Suh, YJ | 1 |
| Lee, CC; Liu, JJ; Liu, SC; Sun, FJ; Zeng, YH | 1 |
| Cheng, K; Niu, J; Song, Z; Wang, J; Zhang, Y | 1 |
| Like Zhong, -; Luo Fang, -; Qilu Fang, -; Qinglin Li, -; Wenxiu Xin, -; Yajun Qi, - | 1 |
| Gunji, R; Kakiuchi, S; Kaku, K; Kurihara, Y; Naito, Y; Senda, M; Utsunomiya, K | 1 |
| Chen, M; Chen, W; Chen, Y; Li, P; Wang, B; Wang, G | 1 |
| Buch, A; Dunsky, A; Eldor, R; Keinan-Boker, L; Kis, O; Lopez, A; Marcus, Y; Osher, E; Rubin, A; Sofer, Y; Stern, N | 1 |
| Iizuka, K; Kato, T; Liu, Y; Mizuno, M; Nonomura, K; Takao, K; Yabe, D; Yasuda, M | 1 |
| Gorgojo-Martínez, JJ; Hallén, N; Hunt, B; Malkin, SJP; Martín, V | 1 |
| Hashimoto, N; Kawai, H; Ohara, T; Onishi, T; Sawada, T; Shimane, A; Takaya, T; Taniguchi, Y; Uzu, K; Yasaka, Y | 1 |
| Abd El-Twab, SM; Abdel-Moneim, A; El-Shahawy, A; Elden, ZE; Taha, M; Yousef, AI | 1 |
| Abd El Fattah, MA; Ahmed, MAE; Eid, NI; Gamal El Din, AA; Gamil, NM; Maklad, YA | 1 |
| Dronamraju, N; Ekholm, E; Garcia-Sanchez, R; Jabbour, SA; Johnsson, E; Lind, M; Vilsbøll, T | 1 |
| Abdalla, O; Dessouki, A; Kilany, O; Sasaki, K; Sayed, N; Shimoda, M; Yoshida, T | 1 |
| Bgatova, NP; Dashkin, MV; Khotskina, AS; Klein, T; Klimontov, VV; Konenkov, VI; Korbut, AI; Muraleva, NA; Orlov, NB; Taskaeva, IS; Zavyalov, EL | 1 |
| Flatt, PR; Irwin, N; Moffett, RC; Tanday, N | 1 |
| Barzel, B; Burke, SL; Cooper, ME; Eikelis, N; Gueguen, C; Head, GA; Jackson, KL; Jandeleit-Dahm, KAM; Jha, JC; Lambert, GW; Lim, K; Sata, Y; Thomas, MC; Watson, AMD | 1 |
| Chen, Y; Fang, W; He, S; Huang, L; Li, B; Li, X; Li, Y; Liu, G; Liu, R; Wang, Z; Yin, H | 1 |
| Avogaro, A; Consoli, A; Fadini, GP; Morieri, ML; Purrello, F; Sesti, G | 1 |
| Chin, HJ; Ferrannini, E; Lim, S; Moon, JH; Shin, Y | 1 |
| Bolla, SR; Chen, Y; Gong, G; Li, Y; Veeraraghavan, VP; Xu, C; Zhang, C; Zhang, M | 1 |
| Chou, TW; Jhuo, SJ; Lai, WT; Lee, KT; Lin, YH; Liu, IH; Tsai, WC; Wu, BN | 1 |
| Li, M; Song, J; Ying, M; Zhuang, Y | 1 |
| Aso, Y; Iijima, T; Jojima, T; Sakurai, S; Tomaru, T; Usui, I | 1 |
| Cai, J; Gao, F; Guo, J; Hao, W; Li, T; Liu, H; Liu, T; Ma, L; Xu, Z; Yan, H; Yang, Y | 1 |
| Asai, K; Hoshika, Y; Ishikawa, M; Iwasaki, YK; Kodani, E; Kubota, Y; Maruyama, M; Miyamoto, M; Miyauchi, Y; Mozawa, K; Ogano, M; Shimizu, W; Takano, H; Tanabe, J; Tara, S; Tokita, Y; Tsukada, Y; Yamamoto, T; Yodogawa, K | 1 |
| Jiang, XY; Qu, Q; Sun, JY; Tang, C; Wang, ZY; Zheng, XD | 1 |
| Davies, MJ; George, JT; Inzucchi, SE; Johansen, OE; Khunti, K; Sattar, N; Trivedi, P; Zwiener, I | 1 |
| Alam, MZ; Alghamdi, BS; Alshehri, FS; Ashraf, GM; Tarazi, FI; Tayeb, HO | 1 |
| Adolph, TE; Folie, S; Haas, S; Haubner, BJ; Hornsteiner, F; Kaser, S; Radlinger, B; Ress, C; Salvenmoser, W; Salzmann, K; Schuetz, T; Tilg, H; Weiss, B | 1 |
| Kang, L; Liu, Y; Wu, M; Xu, B; Xu, J | 1 |
| Ahmad, T; Bissember, AC; Bleasel, M; Canales, J; Caruso, V; Chellappan, DK; D'Andrea, G; Deans, BJ; Eri, R; Grewal, AK; Guven, N; Iglesias, M; Ishaq, M; Jacobson, G; Loh, HL; Ng, WY; Nowak, K; Pasupuleti, M; Raffaeli, W; Randall, C; Ronci, M; Scowen, P; Shastri, M; Smith, JA; Southam, B; Tan, E; Tran, D; Vicario, C; Vicenzi, S; Wu, Y; Xin, JTZ; Yang, C; Yee, CW; Zuccarini, M | 1 |
| Lei, J; Wei, Y; Zhang, H; Zhou, R | 1 |
| Barreto, J; Breder, I; Cintra, RM; de Carvalho, LSF; Guerra-Júnior, G; Kimura-Medorima, ST; Munhoz, DB; Muscelli, E; Nadruz, W; Quinaglia, T; Soares, AAS; Sposito, AC; Wolf, VLW | 1 |
| Buranapin, S; Chattipakorn, N; Euathrongchit, J; Leerapun, A; Phrommintikul, A; Phrueksotsai, S; Pinyopornpanish, K; Thongsawat, S | 1 |
| Chrysafi, P; Feigh, M; Mantzoros, CS; Perakakis, N; Veidal, SS | 1 |
| Isoda, H; Matsukawa, T; Motojima, H; Sato, Y; Takahashi, S; Villareal, MO | 1 |
| Albiero, M; Avogaro, A; Bonora, BM; Fadini, GP; Iori, E; Marescotti, MC; Vitturi, N; Zatti, G | 1 |
| Aoki, C; Aso, Y; Kato, K; Niitani, T; Sagara, M; Suzuki, K; Wakamatsu, S; Yanagi, K | 1 |
| Hu, QP; Lai, XP; Li, G; Li, JQ; Li, X; Liu, JX; Liu, YT; Wu, JG; Wu, QG; Zhang, Y; Zhang, ZD | 1 |
| Gao, HK; Kengne, AP; Mazidi, M; Rezaie, P | 1 |
| Chen, G; Kaneko, S; Mayoux, E; Nagashimada, M; Nagata, N; Ni, Y; Ota, T; Xu, L; Zhuge, F | 1 |
| Amadid, H; Færch, K; Jørgensen, ME; Karstoft, K; Nielsen, LB; Persson, F; Ried-Larsen, M | 1 |
| Ishida, H; Nakamoto, S; Osonoi, T; Osonoi, Y; Saito, M; Tamasawa, A | 1 |
| Choi, JW; Kim, SL; Lee, CW; Lee, J; Park, YI; Seo, JY | 1 |
| Hirose, T; Ikehara, K; Kanda, E; Kumashiro, N; Miyagi, M; Shigiyama, F; Uchino, H | 1 |
| Akiyama, Y; Inoue, K; Inukai, K; Ito, D; Morimoto, Y; Noda, M; Saito, D; Shimada, A; Shimizu, S; Yanagisawa, M | 1 |
| Aronson, R; Brown, RE; Gupta, N | 1 |
| Kaku, K; Suganami, H; Tobe, K | 1 |
| Güllich, A; Manfredini, V; Oliveira, P; Piccoli, J; Pilar, B; Ströher, D | 1 |
| Abe, T; Fujihara, K; Ishizawa, M; Kaku, K; Matsubayashi, Y; Nojima, T; Osawa, T; Sone, H; Suganami, H; Tanaka, S; Yamamoto, M; Yoshida, A | 1 |
| Ferdinand, KC; Salsali, A; Seman, L | 1 |
| Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M | 1 |
| Maegawa, H; Nakamura, I; Tabuchi, H; Tobe, K; Uno, S | 3 |
| Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Öhman, P | 1 |
| Chen, S; Duan, H; Hou, B; Li, F; Shi, Y; Wei, J; Wu, H; Zhang, H; Zhao, L | 1 |
| Cain, V; Dekkers, CCJ; Heerspink, HJL; Sjöström, CD; Stefansson, BV; Wheeler, DC | 1 |
| Bell, KF; Chakravarty, A; Dhankhar, P; Rastogi, M | 1 |
| Dobashi, S; Fujii, T; Hashimoto, H; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T | 1 |
| Geng, X; He, J; Huang, W; Jia, Y; Lei, L; Meng, X; Su, L; Wang, L; Yang, B; Zhang, S; Zhou, H | 1 |
| Avogaro, A; Baldi, I; Bottigliengo, D; Consoli, A; Fadini, GP; Giaccari, A; Sesti, G; Zatti, G | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, S; Öhman, P; Wang, H | 1 |
| Abdel-Wahab, AF; Al-Harizy, RM; Bamagous, GA; ElSawy, NA; Ghamdi, SSA; Ibrahim, IA; Shahzad, N | 1 |
| Cheng, G; George, J; Haneda, M; Kawamori, R; Lee, C; Lee, J; Miyamoto, Y; Shiki, K; Solimando, F; Suzaki, K | 1 |
| Fukuhara, A; Nishitani, S; Okuno, Y; Otsuki, M; Shimomura, I; Shin, J | 1 |
| Azuma, K; Iizuka, T; Inoue, K; Maruyama, S; Matsuzawa, Y; Mukai, S; Nakai, K; Nishikawa, T; Omura, M; Saito, J; Tsurutani, Y | 1 |
| Dunham, MW; Hurren, KM | 1 |
| Miyamoto, L; Tsuchiya, K | 1 |
| Scheen, AJ | 2 |
| Henry, RR; McCrimmon, RJ | 1 |
| Inzucchi, SE; Lupsa, BC | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Ito, YM; Kurihara, Y; Manda, N; Miya, A; Miyoshi, A; Miyoshi, H; Nakamura, A; Niwa, H; Nomoto, H; Takahashi, K; Yamamoto, C | 1 |
| Hong, SG; Hwang, YH; Kang, KY; Kim, KJ; Kim, SJ; Mun, SK; Son, YJ; Yee, ST | 1 |
| Gong, S; Guo, T; Li, L; Xu, S; Zhang, C | 1 |
| Chen, H; Garcia-Sanchez, R; Mathieu, C; Rosenstock, J; Saraiva, GL | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Kurihara, Y; Manda, N; Miya, A; Miyoshi, H; Nakamura, A; Omori, K; Takase, T | 1 |
| Wang, X; Zhai, L | 1 |
| Davis, SN; Hedrington, MS | 1 |
| Ares, J; Delgado, E; Maciá, C; Menéndez, E; Pujante, P; Rodriguez Escobedo, R | 1 |
| Arima, H; Fuse, K; Ida, S; Inoue, H; Kondo, K; Maegawa, H; Miura, K; Miyazawa, I; Morino, K; Murata, K; Ohashi, N; Sato, D; Sekine, O; Tanaka-Mizuno, S; Ugi, S; Yoshimura, M | 1 |
| He, S; Meng, X; Sun, G; Sun, X; Wang, R; Ye, T; Zhang, C | 1 |
| Naik, PR; Nandini, HS | 1 |
| Abdul Rashid, AM; Adams, L; Agah, R; Ahmad Saad, FF; Akay, S; Appiah-Opong, R; Aronson, RD; Asbun, H; Ashong, Y; Ayi, I; Baez, P; Bar-Ad, V; Bay, JL; Bello-Pagan, M; Blackbourn, LAK; Bolan, C; Brierley, L; Cannaday, S; Cannon, TL; Caparrotta, TM; Capitano, M; Colhoun, HM; Coppola, D; Crees, ZD; Crites, D; Devaraj, K; Dumashie, E; Edil, BH; Endo, K; Ferrone, CR; Forcione, DG; Ford, J; Fortuna, D; Garcia, M; Gilad, GM; Gomez, V; Gonzalez, C; Gwira, TM; Han, JY; Hanaki, T; Hardacre, JM; Hester, D; Hidalgo, M; Hirschler, V; Hodul, PJ; Ikeguchi, M; Intersimone, P; Jang, JH; Ji, Z; Johnson, T; Kandel, P; Koh, R; Lee, G; Lee, IG; Leese, GP; Li, J; Liu, X; Lopez, MJ; Maccallini, G; Macdonald, DB; Malek, R; Maley, WR; Martel, G; McCrimmon, RJ; McGurnaghan, SJ; McKeigue, PM; McKnight, JA; Md Noh, MSF; Miao, Y; Mody, K; Molinari, C; Monroe, JF; Mora, HA; Morton, SM; Moyana, TN; Munoz-Jordan, J; Nakamura, S; Neaterour, P; Orcutt, ST; Palmer, JD; Paniccia, A; Park, J; Pearson, ER; Perez, NP; Petrie, JR; Pyatibrat, S; Rademacher, N; Raimondo, M; Ranasinha, N; Reyes, N; Richardson, LC; Ritter, AW; Rivera, A; Rivera-Garcia, B; Rosemurgy, AS; Ross, SB; Sama, A; Sattar, N; Sawata, T; Schulick, RD; Shang, D; Sharp, TM; Shimizu, T; Şirin, B; Sloboda, DM; So, E; Song, X; Srour, SA; Stauffer, J; Suzuki, K; Taguchi, T; Takawira, C; Torphy, R; Trump, DL; Tuffour, I; Ünsal, B; Van Dyne, EA; Vickers, MH; Vitulli, PL; Wallace, MB; Wang-Gillam, A; Waterman, SH; Wei, J; Weinstein, JC; Wild, SH; Williams, N; Winter, J; Woodward, TA; Wu, ES; Wu, J; Yeo, CJ; Yeo, TP; Yeung, V; Zhang, JB | 1 |
| Cai, X; Chen, Y; Gu, S; Ji, L; Nie, L; Shi, L; Yang, W | 1 |
| Chen, C; He, J; Lin, B; Qi, S; Zheng, H | 1 |
| Hara, K; Hirota, Y; Kishi, M; Komada, H; Kuroki, Y; Matsuda, T; Miura, H; Ogawa, W; Ohara, T; Okada, Y; Otowa-Suematsu, N; Sakaguchi, K; So, A; Takeda, A; Tamori, Y; Yamada, T; Yokota, K | 1 |
| Fujii, S; Fujiwara, H; Gunji, R; Kakiuchi, S; Kaku, K; Kameda, H; Kurihara, Y; Senda, M; Tamura, M; Utsunomiya, K | 1 |
| Azuma, M; Dat Le, T; Hiraki, N; Inoue, YH; Omura, F; Yamanaka, M; Yoshimoto, Y | 1 |
| Maegawa, H; Nakamura, I; Tobe, K; Uno, S | 1 |
| Bindels, RJM; de Baaij, JHF; de Galan, BE; Gault, VA; Hoenderop, JGJ; Ma, C; Millar, PJ | 1 |
| Abe, T; Fujihara, K; Ishizawa, M; Kaku, K; Matsubayashi, Y; Nojima, T; Sone, H; Suganami, H; Tanaka, S; Yoshida, A | 1 |
| Arena, S; Avogaro, A; Berchialla, P; Bottigliengo, D; Buzzetti, R; D'Angelo, P; Fadini, GP; Franzetti, I; Sciannameo, V; Vinci, C | 1 |
| Bai, W; Guo, J; Jiang, X; Jiao, R; Li, X; Sun, J; Tang, Y; Tian, L | 1 |
| Boeder, S; Edelman, SV | 1 |
| Han, YH; Hong, SH; Jeon, HD; Kee, JY; Liu, XQ; Mun, JG; Park, J; Park, SH; Zou, QP | 1 |
| García-Sánchez, R; Jacob, S; Johnsson, E; Perl, S; Rosenstock, J | 1 |
| Isaka, H; Kaku, K; Sakatani, T; Toyoshima, J | 1 |
| Dong, Y; Hu, C; Li, N; Li, Y; Liu, J; Ma, X; Snooks, H; Yang, L; Zhang, B; Zhao, X | 1 |
| Dhillon, S | 1 |
| Hwang, YC; Kim, JH; Lee, BW; Lee, WJ | 1 |
| Cao, W; Dong, X; Gong, M; Guo, L; Han, Y; He, R; Liu, Z; Lu, X; Lu, Y; Peng, J; Wu, S; Xie, K; Xu, Y | 1 |
| Austria, JA; Garg, B; Netticadan, T; Parikh, M; Pierce, GN; Raj, P; Yu, L | 1 |
| Briand, F; Galsgaard, ED; Nørgaard, SA; Sand, FW; Sulpice, T; Søndergaard, H; Sørensen, DB | 1 |
| Blak, BT; Fenici, P; Medina, J; Nolan, ST; Rigney, U; Wilding, JPH | 1 |
| Feng, M; Fu, S; Lv, H; Lyu, W; Wang, J; Xu, X | 1 |
| Cho, YK; Jung, CH; Kang, YM; Lee, J; Lee, WJ; Park, JY; Yoo, JH | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Meininger, G; Usiskin, K; Wajs, E; Xi, L; Yale, JF; Yue, D | 1 |
| Ahn, MH; Baek, SH; D'Souza, R; Hong, ST; Hwang, E; Jeon, JS; Jeon, Y; Kang, HJ; Kim, HJ; Kim, SY; Lee, DW; Lee, HS; Lee, SW; Moon, E; Ryu, HS; Seo, CS; Shin, WC | 1 |
| Elze, M; Hruba, V; Langkilde, AM; Parikh, S; Strojek, K; Yoon, KH | 1 |
| Pahor, A; Parikh, S; Rohwedder, K; Soler, NG; Sugg, J; Wilding, JP; Woo, V | 1 |
| del Prato, S; Durán-García, S; Elze, M; Meier, JJ; Nauck, M; Parikh, SJ; Rohwedder, K | 1 |
| Davis, SN; Lamos, EM; Younk, LM | 1 |
| Hardy, E; Johnsson, E; List, J; Parikh, S; Ptaszynska, A | 1 |
| Babu, A | 1 |
| Broedl, UC; Jones, R; Kovacs, CS; Rattunde, H; Seshiah, V; Swallow, R; Woerle, HJ | 1 |
| Bergsma, TT; Gastonguay, MR; MacGregor, TR; Macha, S; Riggs, MM; Seman, L; Staab, A | 1 |
| Jungemann, S; Van Gilder, D | 1 |
| Broedl, UC; Häring, HU; Meinicke, T; Merker, L; Seewaldt-Becker, E; Weimer, M; Woerle, HJ | 2 |
| Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C | 1 |
| Bilo, HJ; Drion, I; Goudswaard, AN; Holleman, F; Kleefstra, N; van Hateren, KJ | 1 |
| Fioretto, P; Kohan, DE; List, JF; Tang, W | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C | 1 |
| Kawanishi, E; Koga, Y; Kuriyama, C; Matsushita, Y; Nomura, S; Sakamaki, S; Ueta, K; Yamamoto, Y | 1 |
| Hardy, E; Jabbour, SA; Parikh, S; Sugg, J | 1 |
| Bays, HE; Canovatchel, W; Law, G; Weinstein, R | 1 |
| Barnett, AH; Goring, S; Hawkins, N; Roudaut, M; Townsend, R; Wood, I; Wygant, G | 1 |
| D'Souza, LJ; Janssen, S; Parkes, DG; Polizzi, C; Tatarkiewicz, K; Villescaz, C; Wang, Y | 1 |
| Iqbal, N; Ji, L; Li, H; List, JF; Ma, J; Mansfield, TA; Ptaszynska, A; T'joen, CL | 1 |
| Capuano, G; Fung, A; Nicolle, LE; Usiskin, K | 1 |
| Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J | 1 |
| Abdul-Ghani, MA; Daniele, G; DeFronzo, RA; Eldor, R; Fiorentino, TV; Merovci, A; Norton, L; Perez, Z; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Seufert, J | 1 |
| Matthaei, S | 1 |
| Schnell, O | 1 |
| Broedl, UC; Cherney, DZ; Fagan, NM; Johansen, OE; Kaspers, S; Partridge, H; Perkins, BA; Soleymanlou, N; Tschirhart, H; Woerle, HJ; Zinman, B | 1 |
| Bakris, GL; Oliva, RV | 1 |
| Condren, AB; Donahue, EP; Farmer, TD; Healey, EC; Kim, K; McCoy, GA; O'Brien, TP; Printz, RL; Shiota, M; Ueta, K | 1 |
| Gangadharan Komala, M; Mather, A | 1 |
| Athanasiadou, E; Bekiari, E; Karagiannis, T; Liakos, A; Mainou, M; Papatheodorou, K; Sarigianni, M; Tsapas, A | 1 |
| Guthrie, R; Slee, A; Traina, S | 1 |
| Del Prato, S; Durán-García, S; Langkilde, AM; Nauck, MA; Parikh, SJ; Rohwedder, K; Sugg, J | 1 |
| Goto, K; Kashiwagi, A; Kazuta, K; Ueyama, E; Utsuno, A; Yoshida, S | 1 |
| Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS | 1 |
| Tahrani, AA | 1 |
| Eguchi, J; Hatanaka, T; Horiguchi, CS; Makino, H; Nakatsuka, A; Nishii, N; Ogawa, D; Tachibana, H; Takei, K; Terami, N; Wada, J; Yamada, H | 1 |
| Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Jiang, J; Law, G; Meininger, G; Nieto, J; Usiskin, K; Wajs, E; Yale, JF; Yue, D | 1 |
| Dou, J; Lu, J; Zhang, Q | 1 |
| Bakris, G; Davies, M; de Zeeuw, D; Kline, I; Mayer, C; Meininger, G; Perkovic, V; Usiskin, K; Vijapurkar, U; Woo, V; Yamout, H | 1 |
| Arnolds, S; Demarest, K; Devineni, D; Ghosh, A; Hompesch, M; Morrow, L; Polidori, D; Rothenberg, P; Sha, S; Spitzer, H | 1 |
| Burgess, L; de Bruin, TW; Hamer-Maansson, JE; Hruba, V; Korányi, L; Schumm-Draeger, PM | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Langslet, G; Leiter, LA; Meininger, G; Millington, D; Vercruysse, F; Xie, J; Yoon, KH | 1 |
| Christensen, M; Gluud, LL; Knop, FK; Storgaard, H; Vilsbøll, T | 1 |
| Brunton, S; Reid, TS | 1 |
| Barnett, AH; Jahagirdar, V | 1 |
| Tan, Y; Yao, F; Zhang, N; Zhang, Q | 2 |
| Ishikawa, H; Kashiwagi, A; Kazuta, K; Takahashi, H; Ueyama, E; Utsuno, A; Yoshida, S | 1 |
| Lin, FQ; Liu, H; Shi, JS; Wang, YY; Yang, J; Zhang, F | 1 |
| Bailey, CJ; List, JF; Morales Villegas, EC; Ptaszynska, A; Tang, W; Woo, V | 1 |
| Plosker, GL | 1 |
| Murosaki, S; Muroyama, K; Ohara, T; Yamamoto, Y | 1 |
| Farrell, K; Ghosh, A; Natarajan, J; Pinheiro, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Vaccaro, N | 1 |
| Hardy, E; Jabbour, S; Parikh, S; Wilding, J | 1 |
| Bode, B; Fung, A; Harris, S; Meininger, G; Stenlöf, K; Sullivan, D; Usiskin, K | 1 |
| Al-Busaidi, N; Rizvi, AA; Rizzo, M | 1 |
| Bowering, K; Grohl, A; Matthaei, S; Parikh, S; Rohwedder, K | 1 |
| Han, N; Liu, Z; Xiao, B; Yin, J; Zhou, C; Zhou, J | 1 |
| White, JR | 1 |
| Bailey, RA; Blonde, L; Meininger, GE; Rupnow, MF; Vijapurkar, U | 1 |
| Del Prato, S; Durán-Garcia, S; Maffei, L; Nauck, M; Parikh, S; Rohwedder, K; Theuerkauf, A | 1 |
| Blesso, CN; Chun, OK; Farrell, N; Lee, SG; Norris, G | 1 |
| Broedl, UC; Haneda, M; Inagaki, N; Kadowaki, T; Koiwai, K; Rattunde, H; Taniguchi, A; Terauchi, Y; Woerle, HJ | 1 |
| Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Leiter, LA; Parikh, SJ; Sugg, J | 1 |
| Edenhofer, I; Kapoor, S; Mitchell, K; Riwanto, M; Rodriguez, D; Segerer, S; Wüthrich, RP | 1 |
| Yang, B; Yu, B; Zhang, L | 1 |
| Broedl, UC; Christiansen, AV; Kim, G; Kovacs, CS; Merker, L; Roux, F; Salsali, A; Seshiah, V; Stella, P; Woerle, HJ | 1 |
| Beck, A; Beyer, U; Boerlin, V; Christ, AD; Ciorciaro, C; Cynshi, O; Ikeda, S; Kadowaki, T; Meyer, M; Takano, Y; Tanaka, R | 1 |
| Bowering, K; Johnsson, E; Matthaei, S; Parikh, S; Rohwedder, K; Sugg, J | 1 |
| Broedl, UC; Christiansen, AV; Haering, HU; Kim, G; Meinicke, T; Merker, L; Roux, F; Salsali, A; Woerle, HJ | 1 |
| Cho, HK; Cho, SW; Choi, KC; Kook, SH; Lee, JC; Lee, KD | 1 |
| Han, P; Iqbal, N; Johnsson, E; Mansfield, T; Min, KW; Ptaszynska, A; T'Joen, C; Wang, B; Yang, W | 1 |
| Bjourson, AJ; Flatt, PR; Gault, VA; Millar, PJ; Moffett, RC; O'Kane, MJ; Pathak, NM; Pathak, V | 1 |
| Alessi, F; Iqbal, N; Mansfield, TA; Parikh, S; Ptaszynska, A; Weber, MA | 1 |
| Nakamura, I; Sugamori, H; Terauchi, Y; Yokote, K | 1 |
| Furuke, S; Kanno, K; Komiya, C; Miyachi, Y; Ogawa, Y; Shiba, K; Shimazu, N; Tsuchiya, K; Yamaguchi, S | 1 |
| Cefalu, WT; de Bruin, TW; Gause-Nilsson, I; Johnsson, E; Leiter, LA; Parikh, S; Xu, J | 1 |
| Aihara, Y; Asada, K; Douhara, A; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Okura, Y; Takeda, K; Yoshiji, H | 1 |
| Bonnes, H; Katz, A; Skolnik, N; Yeh, H | 1 |
| Davies, MJ; Htike, ZZ; Khunti, K; Webb, DR; Youssef, D; Zaccardi, F | 1 |
| Guo, S; Jiang, K; Liu, X; Luo, L; Shen, N; Sun, C; Wang, C; Wang, M; Xu, M; Yang, Y; Yao, L | 1 |
| Araki, E; Asano, M; Ekholm, E; Johnsson, E; Kim, H; Onishi, Y; Yajima, T | 1 |
| Abdul-Ghani, M; Chilton, R; DeFronzo, RA; Del Prato, S | 1 |
| Abiko, A; Atageldiyeva, K; Fujita, Y; Haneda, M; Honjo, J; Makino, Y; Mizumoto, K; Takeda, Y; Takiyama, Y; Yanagimachi, T | 1 |
| Naito, T; Okamoto, A; Sanada, H; Yokokawa, H | 1 |
| Huang, KB; Qin, RZ; Yang, XW; Yang, YX; Zhou, QL | 1 |
| Chen, H; Garcia-Sanchez, R; González González, JG; Hansen, L; Herrera Marmolejo, M; Iqbal, N; Johnsson, E; Mathieu, C | 1 |
| Aggarwal, N; Chen, H; Chin, A; Garcia-Hernandez, P; Hansen, L; Iqbal, N; Johnsson, E; Matthaei, S | 1 |
| Asahina, S; Ishihara, H; Nakao, I; Okitsu, A; Yamaguchi, S | 1 |
| Benetti, E; Chiazza, F; Collino, M; Cutrin, JC; Fantozzi, R; Mastrocola, R; Mayoux, E; Nigro, D; Vitarelli, G | 1 |
| Amini, S; Eriksson, JW; Johnsson, E; Lundkvist, P; Pereira, MJ; Sjöström, CD | 1 |
| Norris, KM; Okie, W; Pazdro, R; Yakaitis, CL | 1 |
| Cui, W; Li, D; Song, Y; Tang, H; Wang, T; Zhai, S; Zhang, J | 1 |
| Dalama, B; Mesa, J | 1 |
| Broedl, UC; Heer, M; Heise, T; Jordan, J; Lund, SS; Macha, S; Mattheus, M; Wanner, C; Woerle, HJ | 1 |
| Hirate, M; Kutoh, E; Murayama, T; Wada, A | 1 |
| Hamada, K; Takakura, S; Takasu, T | 1 |
| Hu, J; Tan, X; Zhang, S; Zhou, M; Zou, P | 1 |
| Abdulsalim, S; Chakraborty, I; Devi, R; Mali, G; Unnikrishnan, MK | 1 |
| Davidson, JA; Sloan, L | 1 |
| Bour, L; Brendel, M; Broedl, UC; Häring, HU; Haupt, A; Machicao, F; Salsali, A; Staiger, H; Woerle, HJ; Zimdahl, H | 1 |
| Chu, L; Gao, Y; Li, J; Liu, H; Ma, Z; Wang, W; Yao, W; Yi, J | 1 |
| Busch, S; Kostev, K; Pscherer, S; Rist, R; Scheerer, MF | 1 |
| Du, J; Jia, M; Qin, LP; Wu, JZ; Xing, WW; Zhang, H | 1 |
| Du, J; Huang, BK; Jia, M; Qin, LP; Sun, LN; Wu, JZ; Xing, WW; Zhang, H | 1 |
| Dong, J; Liang, C; Lin, S; Qi, X; Ren, K; Shen, J; Wu, Y; Yuan, L | 1 |
| Alcorn, J; Felmlee, MA; Krol, ES; Muir, AD; Simko, E; Woo, G | 1 |
| Caminiti, R; Cuzzocrea, S; Dal Toso, R; Di Paola, R; Esposito, E; Mazzon, E; Pressi, G; Riccardi, L | 1 |
| Henderson, A; Hendrich, S; Hostetter, J; Lee, K; Liu, Z; Wannemuehler, M; Ye, Z | 1 |
| Hu, B; Li, DQ; Wang, CF; Xue, HY | 1 |
| Benhabilès, N; Crombé, F; Geeraert, B; Geuns, JM; Holvoet, P; Hulsmans, M | 1 |
| Berniakovich, I; Giorgio, M; Minucci, S; Pelicci, PG; Petroni, K; Porrini, M; Rapisarda, P; Reforgiato Recupero, G; Riso, P; Stendardo, M; Titta, L; Tonelli, C; Trinei, M | 1 |
| Dobbins, RL; Hussey, EK; Kapur, A; Layko, D; Murray, SC; Nunez, DJ; O'Connor-Semmes, RL; Stockman, NL; Stoltz, RR | 1 |
| Birt, DF; Brummer, EC; Kineman, BD; Paiva, NL | 1 |
| Feng, Y; Kasichayanula, S; List, J; Pfister, M; Zhang, L | 1 |
| Awney, HA; El-Maghrabi, S; Massoud, MI | 1 |
| Huang, BK; Huang, LZ; Qin, LP; Rahman, K; Wei, L; Zhao, HF | 1 |
| Ansari, Z; Buyse, JG; Daneshyar, M; Darras, VM; Everaert, N; Geuns, JM; Willemsen, H | 1 |
| Dobbins, RL; Golor, G; Hussey, EK; Kapitza, C; Kapur, A; Mikoshiba, I; O'Connor-Semmes, R; Tao, W | 1 |
| Lynch, B; Roberts, A; Simon, R | 1 |
| Chattopadhyay, N; Dwivedi, AK; Gupta, V; Khan, K; Khan, MP; Maurya, R; Mishra, JS; Rawat, P; Sanyal, S; Sharan, K; Siddiqui, JA; Swarnkar, G | 1 |
| Gong, J; Li, F; Meng, X; Peng, Y; Tang, H; Xiao, F | 1 |
| Chen, JM; Thompson, LU; Truan, JS | 1 |
| Kise, M; Morikawa, K; Nonaka, S; Okuhara, Y; Tsai, YY; Usuki, S; Yu, RK | 1 |
| Giddings, JC; Ikemura, M; Sasaki, Y; Yamamoto, J | 1 |
| Bolinder, J; Johansson, L; Kullberg, J; Langkilde, AM; Ljunggren, Ö; Parikh, S; Sugg, J; Wilding, J | 1 |
| Arakawa, K; Conway, B; Conway, J; Demarest, K; Du, F; Kuriyama, C; Liang, Y; Liu, Y; Martin, T; Matsushita, Y; Polidori, D; Ueta, K; Ways, K; Xu, J | 1 |
| Chen, Y; Li, Y; Weng, X; Yang, Q; Zhu, X; Zou, L | 1 |
| Hennicken, D; Henry, RR; List, JF; Marmolejo, MH; Murray, AV; Ptaszynska, A | 1 |
| List, JF; Rosenstock, J; Salsali, A; Vico, M; Wei, L | 1 |
| Park, JB; Velasquez, MT | 1 |
| Grasso, P; Leinung, MC | 1 |
| Chen, L; Deng, X; He, Y; Lan, Z; Lin, Q; Lin, Y; Mi, X; Wei, L; Zhang, Y | 1 |
| Canistro, D; Iori, R; Melega, S; Pagnotta, E; Paolini, M; Sapone, A | 1 |
| Azuma, H; Hayashi, N; Inoue, S; Kaku, K; Kiyosue, A; Langkilde, AM; Matsuoka, O; Parikh, S; Tokudome, T | 1 |
| Chen, LH; Leung, PS | 1 |
| Ferrannini, E; Hantel, S; Pinnetti, S; Seewaldt-Becker, E; Seman, L; Woerle, HJ | 1 |
| Hiai, H; Itani, T; Kondo, S; Morimitsu, Y; Okada, K; Osawa, T; Ozeki, M; Tashiro, T; Toyokuni, S; Uchida, K | 1 |
| Agger, A; Colombo, M; Gregersen, S; Hermansen, K; Jeppesen, PB; Jepsen, M; Kruhøffer, M; Orntoft, T; Rolfsen, SE; Xiao, J | 1 |
| Abbott, TP; Baek, JS; Kim, HY; Lee, SB; Moon, TW; Park, CS; Park, KH | 1 |
| Aoki, H; Horio, F; Osawa, T; Tsuda, T; Uchida, K | 1 |
| Chen, J; Tan, KP; Thompson, LU; Ward, WE | 1 |
| Awaad, AS; El-Sayed, NH; Mabry, TJ | 1 |
| Cho, SH; Choi, SW; Choi, Y; Rhee, SJ | 1 |
| Hayakawa, T; Mishima, T; Ozeki, K; Tsuge, H | 1 |
| Cao, D; Kim, CH; Park, ES; Shin, BS; Yoo, SD; Yoon, CH | 1 |
| Boozer, CN; Herron, AJ | 1 |
| Gao, Y; Guo, P; Li, YF; Liang, QD; Ma, BP; Ma, ZC; Tan, HL; Tan, W; Wang, SQ; Zhou, Z | 1 |
| Lee, P; Prasad, K | 1 |
| Aulmann, W; Kleber, M; Koehl, W; Messinger, H | 1 |
| Aukema, H; Bankovic-Calic, N; Kovacs, H; Nitschmann, E; Ogborn, M; Weiler, HA | 1 |
| GOLDBERG, L | 1 |
| Halverson, AW; Miller, R; Olson, OE; Palmer, IS; Smith, C | 1 |
| Cokelaere, M; Daenens, P; Darras, V; Decuypere, E; Kühn, ER; Van Boven, M | 1 |
| Hazama, M; Maitani, Y; Nagai, T; Qi, XR; Tojo, H | 1 |
| Jenab, M; Thompson, LU | 1 |
| Chansouria, JP; Jahromi, MA; Manickam, M; Ramanathan, M; Ray, AB | 1 |
| Matsui, H; Shoda, T; Takada, K; Takahashi, M; Toyoda, K; Uneyama, C | 1 |
| Che, QM; Koike, K; Li, Y; Metori, K; Sato, T; Takahashi, S | 1 |
| Prasad, K | 1 |
| Che, QM; Koike, K; Li, Y; Metori, K; Takahashi, S | 1 |
| Cokelaere, M; Daenens, P; Darras, VM; Decuypere, E; Flo, G; Kühn, ER; Van Boven, M; Vermaut, S | 1 |
| Anai, M; Arakawa, K; Asano, T; Funaki, M; Kikuchi, M; Nawano, M; Oka, Y; Oku, A; Saito, A; Ueta, K | 1 |
| Arakawa, H; Kodera, T; Morishima, H; Morita, M; Nishimura, S; Ohkubo, M; Okura, A | 1 |
| Furukawa, F; Hirose, M; Ikeda, T; Imazawa, T; Kasahara, K; Nishikawa, A; Takahashi, M | 1 |
| Cokelaere, M; Daenens, P; Decuypere, E; Flo, G; Van Boven, M; Vermaut, S | 1 |
| Futakuchi, M; Hirose, M; Kimoto, N; Kono, T; Lin, C; Nishibe, S; Shirai, T; Yamaguchi, T | 1 |
| Adachi, T; Iwakura, I; Kitamura, K; Okamoto, Y; Oku, A; Saito, A; Seino, Y; Shihara, N; Tsuda, K; Ueta, K; Yamada, Y; Yano, H; Yasuda, K | 1 |
| Rickard, SE; Thompson, LU; Yuan, YV | 1 |
| Hagiwara, A; Imaida, K; Ito, N; Kadota, T; Koda, T; Miyashita, K; Nakamura, M; Nakanishi, T; Sano, M; Shirai, T; Tamano, S | 1 |
| Alexander, JC; Hill, DC; Philbrick, DJ | 1 |
| Clarke, RM | 1 |
| Campbell, LD; Marquardt, RR; Ward, T | 1 |
| Aze, Y; Hayashi, S; Hayashi, Y; Imaida, K; Imazawa, T; Takahashi, M; Toyoda, K | 1 |
| Chengjiany, B; Eryi, X; Haodong, S; Reiming, S; Xili, L; Yuengming, W; Zhiyian, H | 1 |
| Gregory, JF; Sartain, DB; Trumbo, PR | 1 |
39 review(s) available for glucose, (beta-d)-isomer and Body Weight
| Article | Year |
|---|---|
Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials.
Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Thiophenes | 2019 |
Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Metformin; Peptides; Sodium-Glucose Transporter 1; Venoms | 2018 |
[Sodium-Glucose Transporters as a Therapeutic Target for Diabetes from the Viewpoint of Drug Discovery and Pharmacotherapy].
Topics: Body Weight; Carbonates; Diabetes Mellitus; Drug Discovery; Energy Metabolism; Glucosides; Humans; Hypoglycemic Agents; Molecular Targeted Therapy; Phloretin; Phlorhizin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
SGLT inhibitor adjunct therapy in type 1 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Glucosides; Glycosides; Humans; Hypoglycemic Agents; International Cooperation; Multicenter Studies as Topic; Observational Studies as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 1 | 2018 |
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Bone and Bones; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Kidney; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
Oral semaglutide for the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Sitagliptin Phosphate | 2019 |
Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
Topics: Administration, Oral; Age Factors; Age of Onset; Benzhydryl Compounds; Body Weight; China; Cholesterol; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Expenditures; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Dapagliflozin: A Review in Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Europe; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Pregnancy; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
Topics: Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Effects of dapagliflozin on cardiovascular risk factors.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Risk Factors; Sodium-Glucose Transport Proteins | 2013 |
Canagliflozin for the treatment of type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin-Secreting Cells; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
[SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin].
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Netherlands; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2013 |
Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2014 |
[SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes].
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Kidney Concentrating Ability; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult | 2014 |
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Reabsorption; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Empagliflozin for the treatment of Type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Odds Ratio; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2014 |
Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Insulin Resistance; Randomized Controlled Trials as Topic; Renal Elimination; Sodium-Glucose Transporter 2 Inhibitors; Systematic Reviews as Topic; Thiophenes; Treatment Outcome | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Kidney; Lipids; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Empagliflozin for the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Dapagliflozin: a review of its use in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Biological Availability; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Renal Elimination; Renal Reabsorption; Sodium-Glucose Transport Proteins; Treatment Outcome | 2014 |
Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; United States | 2015 |
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Topics: B-Cell Activating Factor; Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasting; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Network Meta-Analysis; Odds Ratio; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2016 |
Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Odds Ratio; Randomized Controlled Trials as Topic; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss | 2017 |
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Proteinuria; Risk; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Vascular Stiffness | 2016 |
Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Reproductive Tract Infections; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
83 trial(s) available for glucose, (beta-d)-isomer and Body Weight
| Article | Year |
|---|---|
Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Endothelium; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2022 |
The effect of circuit resistance training, empagliflozin or "vegeterranean diet" on physical and metabolic function in older subjects with type 2 diabetes: a study protocol for a randomized control trial (CEV-65 trial).
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Body Composition; Body Weight; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Mediterranean; Diet, Vegetarian; Exercise; Female; Glucosides; Humans; Male; Resistance Training; Sodium-Glucose Transporter 2 Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2019 |
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Treatment Outcome | 2020 |
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.
Topics: Adiponectin; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Fibrinolysis; Glucosides; Humans; Leptin; Plasminogen Activator Inhibitor 1 | 2020 |
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
Topics: 3-Iodobenzylguanidine; Aged; Benzhydryl Compounds; Blood Pressure; Body Weight; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Double-Blind Method; Electrocardiography, Ambulatory; Female; Glucosides; Heart Rate; Humans; Male; Middle Aged; Myocardial Infarction; Parasympathetic Nervous System; Radionuclide Imaging; Radiopharmaceuticals; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System; Uric Acid | 2020 |
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2021 |
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus.
Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Composition; Body Weight; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glyburide; Glycated Hemoglobin; Hand Strength; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2021 |
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Non-alcoholic Fatty Liver Disease | 2021 |
Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Male; Middle Aged; Particle Size; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Middle Aged; Overweight; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).
Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Prediabetic State; Research Design; Risk Factors | 2017 |
Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
Topics: Administration, Oral; Aged; Asian People; Blood Glucose; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Prospective Studies; Thiophenes; Treatment Outcome; Waist Circumference | 2018 |
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Treatment Outcome; Young Adult | 2017 |
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.
Topics: Asian People; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Japan; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Predictors of the response of HbA1c and body weight after SGLT2 inhibition.
Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Black or African American; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; United States | 2018 |
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
Topics: Anti-Obesity Agents; Benzhydryl Compounds; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2018 |
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Middle Aged; Sodium-Glucose Transport Proteins | 2018 |
Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Treatment Outcome | 2018 |
Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study.
Topics: Adult; Aged; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Male; Middle Aged; Sitagliptin Phosphate; Thiophenes | 2018 |
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison
Topics: Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Substitution; Energy Metabolism; Female; Glucosides; Humans; Male; Middle Aged; Pioglitazone; Treatment Outcome | 2019 |
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Topics: Adipose Tissue; Adult; Aged; Biomarkers; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Muscle, Skeletal; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2019 |
Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin.
Topics: Adipose Tissue; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Insulin Resistance; Lipolysis; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2019 |
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2019 |
Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 1; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Thiophenes | 2019 |
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
Topics: Aged; Biomarkers; Blood Glucose; Body Weight; Canagliflozin; Comorbidity; Diabetes Mellitus, Type 2; Disease Progression; Diuresis; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Urinary Tract Infections | 2013 |
[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2013 |
[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Long-Term Care; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Topics: Aged; Balanitis; Benzhydryl Compounds; Blood Glucose; Body Weight; Candidiasis, Vulvovaginal; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glipizide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2013 |
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Treatment Outcome; Weight Loss | 2014 |
Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Models, Biological; Sodium-Glucose Transporter 2 Inhibitors | 2013 |
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Sulfonylurea Compounds; Treatment Outcome | 2013 |
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Topics: Aged; Benzhydryl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triazoles; Triglycerides; Weight Loss | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss | 2014 |
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose; Glucosides; Humans; Male; Middle Aged; Obesity; Overweight; Sodium-Glucose Transport Proteins; Thiophenes; Treatment Outcome | 2014 |
Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Topics: Adult; Asian People; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2014 |
Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Recurrence; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Urinary Tract Infections; Young Adult | 2014 |
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucose; Glucose Clamp Technique; Glucosides; Humans; Hyperglycemia; Insulin; Male; Metformin; Middle Aged; Muscles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors | 2014 |
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 1; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2014 |
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Time Factors | 2014 |
The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
Topics: Adult; Age Factors; Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Behavior; Humans; Hypoglycemic Agents; Male; Middle Aged; Personal Satisfaction; Pyrazines; Quality of Life; Self Efficacy; Sex Factors; Sexual Behavior; Sitagliptin Phosphate; Thiophenes; Triazoles; Weight Loss | 2014 |
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections | 2014 |
Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.
Topics: Aged; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Thiophenes | 2015 |
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Water-Electrolyte Balance; Weight Loss | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Male; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2014 |
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Male; Middle Aged; Thiophenes | 2014 |
Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
Topics: Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Europe; Feasibility Studies; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Membrane Transport Modulators; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; South Africa | 2015 |
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 dia
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2015 |
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Canagliflozin; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Postprandial Period; Thiophenes | 2015 |
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuresis; Double-Blind Method; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Osmolar Concentration; Thiophenes; Urinary Tract Infections | 2015 |
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Urinary Tract Infections | 2015 |
Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.
Topics: Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2014 |
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study.
Topics: Adult; Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome | 2015 |
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
Topics: Analysis of Variance; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Risk Factors; Treatment Outcome; Urinary Tract Infections | 2015 |
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2015 |
A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Exercise Therapy; Fasting; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Ketones; Male; Metformin; Middle Aged | 2015 |
Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Urinary Tract Infections | 2015 |
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2015 |
Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos | 2016 |
Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Blood Pressure Determination; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Heart Rate; Hemorheology; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Renin-Angiotensin System; Systole; Uric Acid | 2016 |
Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
Topics: Aged; Asian People; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Treatment Outcome | 2016 |
[Effect of dapagliflozin on cardiovascular risk factors].
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electrolytes; Endpoint Determination; Glucosides; Glycated Hemoglobin; Hospitalization; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Treatment Outcome | 2016 |
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2016 |
One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2016 |
Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
Topics: Adiponectin; Aged; Asian People; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Reproductive Tract Infections; Thiophenes; Treatment Outcome; Urinary Tract Infections | 2016 |
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.
Topics: Adipose Tissue; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glucose Intolerance; Glucosides; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Obesity; Peptides; Prediabetic State; Treatment Outcome; Venoms; Weight Loss | 2017 |
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glucosides; Glycosuria; Half-Life; Humans; Insulin; Male; Middle Aged; Obesity; Overweight; Prodrugs; Water-Electrolyte Balance | 2010 |
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Weight Loss | 2010 |
Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2012 |
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Topics: Adipose Tissue; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome | 2012 |
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult | 2012 |
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2012 |
Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nasopharyngitis; Republic of Korea; Russia; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Thirst; Treatment Outcome; Ukraine; Urination Disorders; Weight Loss | 2013 |
200 other study(ies) available for glucose, (beta-d)-isomer and Body Weight
| Article | Year |
|---|---|
Olprinone, a specific phosphodiesterase (PDE)-III inhibitor, reduces the development of multiple organ dysfunction syndrome in mice.
Topics: Alanine Transaminase; Alkaline Phosphatase; Amylases; Animals; Apoptosis; Ascitic Fluid; Aspartate Aminotransferases; bcl-2-Associated X Protein; Bicarbonates; Bilirubin; Blood Gas Analysis; Body Weight; Cell Count; Creatinine; Fas Ligand Protein; Hydrogen-Ion Concentration; Imidazoles; Intercellular Adhesion Molecule-1; Interleukin-1beta; Kidney; Lipase; Liver; Lung; Male; Mice; Mice, Inbred Strains; Multiple Organ Failure; Nitrates; Nitrites; P-Selectin; Pancreas; Phosphodiesterase 3 Inhibitors; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyridones; Survival Analysis; Tumor Necrosis Factor-alpha; Tyrosine; Zymosan | 2011 |
Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Body Weight; Cytokines; Enzyme Activation; Fas Ligand Protein; Gene Expression Regulation; Glutamine; Inflammation; Lipid Peroxidation; Male; Mice; Multiple Organ Failure; Neutrophil Infiltration; Nitric Oxide; Peritoneal Cavity; Poly Adenosine Diphosphate Ribose; Poly(ADP-ribose) Polymerases; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Tyrosine; Zymosan | 2011 |
Treatment with Fms-like tyrosine kinase 3 ligand reverses lung dendritic cell immunoparalysis and ameliorates zymosan-induced secondary lung injury in mice.
Topics: Animals; Antigens, CD; Body Weight; Dendritic Cells; fms-Like Tyrosine Kinase 3; Interleukin-10; Interleukin-12; Ligands; Lung; Lung Injury; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Multiple Organ Failure; Survival Rate; Zymosan | 2012 |
Ubiquitin-proteasome-dependent proteolytic activity remains elevated after zymosan-induced sepsis in rats while muscle mass recovers.
Topics: Animals; Body Weight; Chymotrypsin; Eating; Male; Muscle, Skeletal; Proteasome Endopeptidase Complex; Protein Subunits; Rats; Rats, Wistar; Sepsis; Ubiquitin; Zymosan | 2005 |
A comparison of elderly and adult multiple organ dysfunction syndrome in the rat model.
Topics: Aging; Animals; Apoptosis; Body Weight; Bronchoalveolar Lavage Fluid; Calcium; Carbon Dioxide; Cytokines; Disease Models, Animal; Lung; Macrophages, Alveolar; Male; Multiple Organ Failure; Myocardium; Organ Size; Oxygen; Partial Pressure; Rats; Rats, Sprague-Dawley; Zymosan | 2006 |
RES response to hypophysectomy in the rat.
Topics: Adrenal Glands; Animals; Blood Volume; Body Weight; Carbon; Hypophysectomy; Injections, Intravenous; Liver; Male; Mononuclear Phagocyte System; Organ Size; Phagocytosis; Rats; Regional Blood Flow; Spleen; Zymosan | 1967 |
Role of bacterial endotoxins of intestinal origin in rat heat stress mortality.
Topics: Animals; Body Weight; Drug Tolerance; Endotoxins; Escherichia coli; Hot Temperature; Intestines; Male; Rats; Rats, Inbred Strains; Stress, Physiological; Zymosan | 1983 |
Impaired in vitro bactericidal power of polymorphonuclear leukocytes in patients with protein calorie malnutrition.
Topics: Adult; Body Weight; Deglutition Disorders; Female; Humans; In Vitro Techniques; Male; Middle Aged; Neutrophils; Oxygen Consumption; Parenteral Nutrition; Parenteral Nutrition, Total; Phagocyte Bactericidal Dysfunction; Protein-Energy Malnutrition; Serum Albumin; Transferrin; Zymosan | 1983 |
Prolonged changes in protein and amino acid metabolism after zymosan treatment in rats.
Topics: Acute Disease; Amino Acids; Animals; Body Weight; Critical Illness; Disease Models, Animal; Liver; Male; Muscle Proteins; Muscle, Skeletal; Organ Size; Rats; Rats, Inbred Lew; Zymosan | 1994 |
Active oxygen generation by alveolar macrophage in mice treated with carcinogen and promoter.
Topics: 4-Nitroquinoline-1-oxide; Animals; Body Weight; Carcinogens; Cocarcinogenesis; Glycerol; Luminescent Measurements; Lung; Macrophages, Alveolar; Male; Mice; Mice, Inbred Strains; Reactive Oxygen Species; Zymosan | 1993 |
The effect of acute nonbacterial dependent peritonitis on lung and liver oxidant stress and antioxidant activity.
Topics: Animals; Antioxidants; Body Weight; Catalase; Diuresis; Glutathione; Glutathione Disulfide; Hematocrit; Liver; Lung; Male; Oxidants; Oxygen; Peritonitis; Rats; Rats, Wistar; Time Factors; Xanthine Dehydrogenase; Xanthine Oxidase; Zymosan | 1993 |
Response to local inflammation of IL-1 beta-converting enzyme- deficient mice.
Topics: Animals; Apolipoproteins; Body Weight; Caspase 1; Cell Movement; Cysteine Endopeptidases; Cytokines; Inflammation; Injections, Subcutaneous; Interleukin-1; Mice; Mice, Mutant Strains; Serum Amyloid A Protein; Turpentine; Zymosan | 1997 |
Organ damage is preceded by changes in protein extravasation in an experimental model of multiple organ dysfunction syndrome.
Topics: Animals; Body Fluid Compartments; Body Temperature; Body Weight; Capillary Permeability; Disease Models, Animal; Extracellular Space; Male; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Proteins; Zymosan | 1997 |
Stem cell factor-deficient mice have a dysregulation of cytokine production during local inflammation.
Topics: Animals; Ascitic Fluid; Body Weight; Cytokines; Disease Models, Animal; Female; Hypoglycemia; Inflammation; Irritants; Mice; Mice, Mutant Strains; Peritoneal Cavity; Peritonitis; Stem Cell Factor; Turpentine; Weight Loss; Zymosan | 1998 |
The cytochrome P450 suicide inhibitor, 1-aminobenzotriazole, sensitizes rats to zymosan-induced toxicity.
Topics: Animals; Body Weight; Cytochrome P-450 Enzyme Inhibitors; Drug Synergism; Enzyme Inhibitors; Inflammation; Leukocyte Count; Male; Microsomes, Liver; Neutrophils; Nitrates; Nitrites; Organ Size; Rats; Rats, Sprague-Dawley; Survival Analysis; Triazoles; Zymosan | 1998 |
Protective effect of N-acetylcysteine on multiple organ failure induced by zymosan in the rat.
Topics: Acetylcysteine; Animals; Body Weight; Disease Models, Animal; Drug Evaluation, Preclinical; Free Radical Scavengers; Leukocyte Count; Male; Multiple Organ Failure; Nitrates; Nitric Oxide; Peritonitis; Random Allocation; Rats; Rats, Sprague-Dawley; Shock, Septic; Survival Analysis; Time Factors; Zymosan | 1999 |
Protective effect of poly(ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat.
Topics: Animals; Benzamides; Body Weight; Disease Models, Animal; Drug Evaluation, Preclinical; Male; Multiple Organ Failure; Niacinamide; Nitrates; Peritonitis; Poly(ADP-ribose) Polymerase Inhibitors; Random Allocation; Rats; Rats, Sprague-Dawley; Time Factors; Zymosan | 1999 |
Interleukin 10 mitigates the development of the zymosan-induced multiple organ dysfunction syndrome in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cytokines; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression Regulation; Hemorrhage; Humans; Hypothermia; Interleukin-10; Lipopolysaccharides; Liver; Lung; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Multiple Organ Failure; Organ Size; Recombinant Proteins; Spleen; Tumor Necrosis Factor-alpha; Zymosan | 1999 |
Vitamin E uncouples joint destruction and clinical inflammation in a transgenic mouse model of rheumatoid arthritis.
Topics: Animals; Antioxidants; Arthritis, Rheumatoid; Body Weight; Disease Models, Animal; Glutathione; Hydrogen Peroxide; Interleukin-1; Isoprostanes; Joints; Leukocytes; Luminescent Measurements; Mice; Mice, Inbred NOD; Mice, Transgenic; Oxidation-Reduction; Tumor Necrosis Factor-alpha; Vitamin E; Zymosan | 2002 |
SOD in rat models of shock and organ failure.
Topics: Animals; Body Weight; Cattle; Disease Models, Animal; Lipid Peroxidation; Liver; Male; Multiple Organ Failure; Peritonitis; Rats; Rats, Inbred Strains; Shock; Shock, Septic; Superoxide Dismutase; Zymosan | 1990 |
Endotoxin does not play a key role in the pathogenesis of multiple organ failure. An experimental study.
Topics: Animals; Body Temperature; Body Weight; Endotoxins; Escherichia coli; Hemorrhage; Lung; Lung Diseases; Male; Mice; Mice, Inbred C3H; Multiple Organ Failure; Organ Size; Spleen; Staphylococcus; Zymosan | 1989 |
Iron deficiency and neutrophil function: different rates of correction of the depressions in oxidative burst and myeloperoxidase activity after iron treatment.
Topics: Animals; Body Weight; Hemoglobins; Iron; Iron Deficiencies; Male; Neutrophils; Oxygen; Peroxidase; Phagocytosis; Rats; Rats, Inbred Strains; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 1987 |
Function of reticuloendothelial system on CCl4 induced liver injury in mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Protein Electrophoresis; Body Weight; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Liver; Male; Mice; Mononuclear Phagocyte System; Organ Size; Phagocytosis; Zymosan | 1985 |
Influence of a change in the activity of the reticuloendothelial system (RES) on the development of adjuvant-induced polyarthritis in the rat.
Topics: Adjuvants, Immunologic; Animals; Arthritis; Beryllium; Body Weight; Endotoxins; Glycoproteins; Inflammation; Injections, Intravenous; Liver; Male; Mononuclear Phagocyte System; Organ Size; Phagocytosis; Phosphates; Rabbits; Rats; Spleen; Time Factors; Zymosan | 1973 |
Hypocholesterolemic Efficacy of Secoisolariciresinol Diglucoside and Its Polymer in Rat.
Topics: Animals; Anticholesteremic Agents; Body Weight; Butylene Glycols; Female; Glucosides; Lipids; Liver; Organ Size; Polymers; Rats; Rats, Wistar | 2021 |
Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients.
Topics: Age Factors; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Retrospective Studies; Weight Loss | 2022 |
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome.
Topics: Adult; Benzhydryl Compounds; Body Weight; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Male; Metabolic Syndrome; Metformin; Middle Aged; Monocytes | 2021 |
Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care.
Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Metformin; Primary Health Care; Weight Loss | 2022 |
Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Retrospective Studies | 2022 |
Dietary supplementation of salidroside alleviates liver lipid metabolism disorder and inflammatory response to promote hepatocyte regeneration via PI3K/AKT/Gsk3-β pathway.
Topics: Abnormalities, Multiple; Animals; Body Weight; Chickens; Craniofacial Abnormalities; Diet, High-Fat; Dietary Supplements; Fatty Liver; Female; Glucosides; Glycogen Synthase Kinase 3; Growth Disorders; Heart Septal Defects, Ventricular; Hepatocytes; Lipid Metabolism; Lipid Metabolism Disorders; Liver; Phenols; Phosphatidylinositol 3-Kinases; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-akt; RNA, Messenger; Triglycerides | 2022 |
Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrimidines; Republic of Korea; Thiazolidinediones; Treatment Outcome | 2022 |
Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin.
Topics: Benzhydryl Compounds; Blood Glucose; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2022 |
Protective effects of polydatin on ileum injury in mice exposed to aflatoxin B1.
Topics: Aflatoxin B1; Animals; Body Weight; Glucosides; Humans; Ileum; Inflammation; Liver; Male; Mice; Oxidative Stress; RNA, Messenger; Stilbenes | 2023 |
Paeony attenuates high fat diet-induced kidney injury via inflammation inhibition.
Topics: Animals; Body Weight; Diet, High-Fat; Glucosides; Inflammation; Kidney; Lipids; Mice; Mice, Inbred C57BL; Myeloid Differentiation Factor 88; Paeonia | 2023 |
Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study).
Topics: Aged; Asian People; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Product Surveillance, Postmarketing; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report.
Topics: Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Sarcopenia; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Administration Routes; Drug Administration Schedule; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Econometric; Models, Statistical; Network Meta-Analysis; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2 Inhibitors; Spain | 2020 |
Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease.
Topics: Benzhydryl Compounds; Body Weight; Cardiometabolic Risk Factors; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascular; Female; Glucose; Glucosides; Hemodynamics; Humans; Lipid Metabolism; Male; Middle Aged; Outcome Assessment, Health Care; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2020 |
Novel polydatin-loaded chitosan nanoparticles for safe and efficient type 2 diabetes therapy: In silico, in vitro and in vivo approaches.
Topics: Animals; Biomarkers; Body Weight; Chitosan; Chlorocebus aethiops; Diabetes Mellitus, Type 2; Drug Carriers; Drug Liberation; Glucosides; Hypoglycemic Agents; Male; Molecular Conformation; Molecular Dynamics Simulation; Nanoparticles; Particle Size; Rats; Rats, Wistar; Safety; Stilbenes; Vero Cells | 2020 |
Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet-fed streptozotocin-treated diabetic rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Food, Fortified; Glucose Transporter Type 2; Glucosides; Hypoglycemic Agents; Inflammation Mediators; Insulin Resistance; Lansoprazole; Male; Oxidative Stress; Pancreas; PPAR gamma; Random Allocation; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes.
Topics: Animals; Antioxidants; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucosides; Hypercholesterolemia; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Male; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
Topics: Animals; Apoptosis; Autophagy; Benzhydryl Compounds; Biomarkers; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression; Glucosides; Immunohistochemistry; Kidney Function Tests; Kidney Glomerulus; Linagliptin; Mice; Mice, Inbred Strains; Mice, Transgenic; Podocytes; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Cell Transdifferentiation; Diabetes Mellitus, Experimental; Diet, High-Fat; Energy Intake; Glucagon; Glucagon-Secreting Cells; Glucosides; Homeodomain Proteins; Hydrocortisone; Insulin; Insulin Resistance; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice, Transgenic; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Trans-Activators | 2020 |
Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes.
Topics: Animals; Baroreflex; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Glucosides; Heart Rate; Male; Perindopril; Rabbits; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System | 2020 |
Total glucosides of paeony (TGP) alleviates Sjogren's syndrome through inhibiting inflammatory responses in mice.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Body Weight; Cytokines; Disease Models, Animal; Gene Expression Regulation; Glucosides; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Paeonia; Saliva; Sjogren's Syndrome; Submandibular Gland | 2020 |
Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Glycated Hemoglobin; Humans; Italy; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prognosis; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Young Adult | 2020 |
Vicenin-2 Treatment Attenuated the Diethylnitrosamine-Induced Liver Carcinoma and Oxidative Stress through Increased Apoptotic Protein Expression in Experimental Rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Apigenin; Apoptosis; Biomarkers, Tumor; Blood Proteins; Body Weight; Carcinoma, Hepatocellular; Diethylnitrosamine; Enzymes; Glucosides; Liver Neoplasms, Experimental; Male; Oxidative Stress; Rats, Wistar; Serum Globulins | 2020 |
Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor.
Topics: Adipokines; Adipose Tissue; Animals; Benzhydryl Compounds; Body Weight; Cell Line; Glucosides; Humans; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Polydatin Attenuates 14.1 MeV Neutron-Induced Injuries via Regulating the Apoptosis and Antioxidative Pathways and Improving the Hematopoiesis of Mice.
Topics: Animals; Antioxidants; Apoptosis; Body Weight; Bone Marrow Cells; Glucosides; Hematopoiesis; Heme Oxygenase-1; Kelch-Like ECH-Associated Protein 1; Lung; Male; Mice, Inbred BALB C; Neutrons; Radiation, Ionizing; Sirtuin 1; Spleen; Stilbenes; Survival Analysis | 2020 |
Standardizing the Effective Correlated Dosage of Olanzapine and Empagliflozin in Female Wistar Rats.
Topics: Animals; Antipsychotic Agents; Benzhydryl Compounds; Body Weight; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Glucosides; Hypoglycemic Agents; Models, Animal; Olanzapine; Rats; Rats, Wistar | 2021 |
Cardioprotective effects of short-term empagliflozin treatment in db/db mice.
Topics: Animals; Benzhydryl Compounds; Body Weight; Cardiotonic Agents; Citrate (si)-Synthase; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, Western; Gene Expression Regulation; Glucosides; Male; Mice; Myocardium; Phosphorylation; Proto-Oncogene Proteins c-akt; Treatment Outcome | 2020 |
Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity.
Topics: Animals; Atherosclerosis; Benzhydryl Compounds; Body Weight; Disease Progression; Glucosides; Inflammation; Lipids; Male; Mice; Neuropeptide Y; Norepinephrine; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System | 2021 |
Asperuloside Enhances Taste Perception and Prevents Weight Gain in High-Fat Fed Mice.
Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Cyclopentane Monoterpenes; Diet, High-Fat; Energy Intake; Ghrelin; Glucosides; Hypothalamus; Insulin; Leptin; Male; Mice; Pro-Opiomelanocortin; Pyrans; Taste Perception; Weight Gain | 2021 |
Chemoprotective Effects of Geraniin against Azoxymethane Induced Colorectal Cancer by Reduction of Inflammatory Reaction.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Azoxymethane; Body Weight; Colorectal Neoplasms; Cytokines; Enzymes; Female; Glucosides; Hydrolyzable Tannins; Inflammation; Male; Oxidative Stress; Rats, Wistar | 2021 |
Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
Topics: Animals; Antigens, CD; Benzhydryl Compounds; Biopsy; Body Composition; Body Weight; Disease Models, Animal; Glucose; Glucosides; Homeostasis; Insulin Resistance; Lactosylceramides; Lipidomics; Liver; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Triglycerides | 2021 |
Upregulation of skeletal muscle PGC-1α through the elevation of cyclic AMP levels by Cyanidin-3-glucoside enhances exercise performance.
Topics: Adenylate Kinase; Animals; Anthocyanins; Blood Glucose; Body Weight; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Cell Line; Cyclic AMP; Feeding Behavior; Glucosides; Lactic Acid; Liver; Male; Mice, Inbred ICR; Mitochondria; Models, Biological; Muscle Fibers, Skeletal; Muscle, Skeletal; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Physical Conditioning, Animal; Swimming; Up-Regulation | 2017 |
Anti-inflammatory effects of rosmarinic acid-4-O-β-D-glucoside in reducing acute lung injury in mice infected with influenza virus.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cinnamates; Cytokines; Depsides; Disease Models, Animal; Glucosides; Lung; Mice; Orthomyxoviridae Infections; Rosmarinic Acid; Survival Analysis; Viral Load | 2017 |
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
Topics: Adipose Tissue; Adiposity; Animals; Benzhydryl Compounds; Biomarkers; Body Weight; Diet, High-Fat; Energy Metabolism; Fatty Acids; Fatty Liver; Glucose; Glucosides; Hypoglycemic Agents; Inflammation; Insulin Resistance; Macrophage Activation; Macrophages; Male; Mice; Muscle, Skeletal; Obesity; Oxidation-Reduction; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Corn silk maysin ameliorates obesity in vitro and in vivo via suppression of lipogenesis, differentiation, and function of adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Line; Cholesterol, LDL; Diet, High-Fat; Flavonoids; Glucosides; Lipogenesis; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Triglycerides; Weight Gain; Zea mays | 2017 |
Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canada; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Registries; Retrospective Studies; Treatment Outcome | 2017 |
Protective Role of Flaxseed Oil and Flaxseed Lignan Secoisolariciresinol Diglucoside Against Oxidative Stress in Rats with Metabolic Syndrome.
Topics: Animals; Antioxidants; Body Weight; Butylene Glycols; Flax; Fructose; Glucose; Glucosides; Humans; Lignans; Linseed Oil; Lipids; Male; Metabolic Syndrome; Oxidative Stress; Protective Agents; Quality of Life; Rats | 2017 |
Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
Topics: Adipose Tissue; Animal Feed; Animals; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Solutions; Sugars; Thiophenes | 2018 |
Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemic Agents; Japan; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Product Surveillance, Postmarketing; Registries; Thiophenes; Treatment Outcome; Triglycerides | 2018 |
Anthocyanins inhibit high glucose-induced renal tubular cell apoptosis caused by oxidative stress in db/db mice.
Topics: Albuminuria; Animals; Anthocyanins; Apoptosis; bcl-2-Associated X Protein; Blood Glucose; Body Weight; Carrier Proteins; Cell Line; Creatinine; Diabetes Mellitus, Experimental; Fasting; Glucose; Glucosides; Grape Seed Extract; Humans; Kidney Tubules; Male; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Mice, Inbred C57BL; Oxidative Stress; Phosphorylation; Proanthocyanidins; Reactive Oxygen Species; Thioredoxins; Triglycerides; Urea | 2018 |
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Blood Pressure; Body Weight; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Health Expenditures; Health Resources; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years; Sulfonylurea Compounds; Thiazolidinediones; United Nations; United States | 2018 |
Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Japan; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Skin Diseases; Thiophenes; Treatment Outcome | 2018 |
Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report.
Topics: Aged, 80 and over; Body Weight; Glucosides; Heart Failure; Hospitalization; Humans; Male; Myocardial Perfusion Imaging; Sympathetic Nervous System; Thiophenes; Treatment Outcome | 2018 |
Dapagliflozin Aggravates Renal Injury via Promoting Gluconeogenesis in db/db Mice.
Topics: Animals; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Blood Urea Nitrogen; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Gluconeogenesis; Glucose; Glucose Tolerance Test; Glucosides; Insulin; Kidney; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Microscopy, Electron, Transmission; ROC Curve; Signal Transduction | 2018 |
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gliclazide; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Italy; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Biphenyl Compounds; Blood Pressure; Body Weight; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Glucosides; Inflammation Mediators; Irbesartan; Kidney; Male; Organ Size; Oxidative Stress; Protective Agents; Rats, Wistar; Tetrazoles | 2018 |
Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes.
Topics: 3-Hydroxybutyric Acid; Adiponectin; Adipose Tissue; Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Gene Expression Profiling; Glucosides; Metabolome; Metabolomics; Mice; Mice, Inbred NOD; Microarray Analysis; Sodium-Glucose Transporter 2 Inhibitors; Transcriptome; Up-Regulation | 2018 |
Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes | 2019 |
Protective Effects of 2,3,5,4'-Tetrahydroxystilbene-2-
Topics: Animals; Biomarkers; Body Weight; Bone and Bones; Disease Models, Animal; Glucosides; Humans; Mice; Organ Size; Osteoporosis; Ovariectomy; Plant Extracts; Protective Agents; Stilbenes; X-Ray Microtomography | 2018 |
Effect of Dapagliflozin on Intestinal Flora in MafA-deficient Mice.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Gastrointestinal Microbiome; Glucosides; Maf Transcription Factors, Large; Male; Mice; Mice, Inbred ICR; Streptozocin | 2018 |
Syringaresinol‑di‑O‑β‑D‑glucoside, a phenolic compound from Polygonatum sibiricum, exhibits an antidiabetic and antioxidative effect on a streptozotocin‑induced mouse model of diabetes.
Topics: Animals; Antioxidants; Biomarkers; Body Weight; Diabetes Mellitus, Experimental; Disease Models, Animal; Fasting; Glucosides; Hypoglycemic Agents; Insulin; Kidney; Lignans; Liver; Male; Mice; Plant Extracts; Polygonatum | 2018 |
Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2019 |
Gastrodin Alleviates Cognitive Dysfunction and Depressive-Like Behaviors by Inhibiting ER Stress and NLRP3 Inflammasome Activation in db/db Mice.
Topics: Animals; Apoptosis; Behavior, Animal; Benzyl Alcohols; Blood Glucose; Body Weight; Cognitive Dysfunction; Depression; Dyslipidemias; Endoplasmic Reticulum Stress; Glucosides; Inflammasomes; Insulin Resistance; Male; Memory; Mice; Models, Biological; Neurons; Neuroprotective Agents; NLR Family, Pyrin Domain-Containing 3 Protein | 2018 |
Action of corilagin on hyperglycemia, hyperlipidemia and oxidative stress in streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Catalase; Diabetes Mellitus, Experimental; Glucosides; Glutathione; Glycated Hemoglobin; Hydrolyzable Tannins; Hyperglycemia; Hyperlipidemias; Insulin; Lipids; Male; Oxidative Stress; Rats; Rats, Wistar; Streptozocin; Superoxide Dismutase | 2019 |
Topics: Adult; Aged; Animals; Antigens, Helminth; Apoptosis; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Carcinogenesis; Cardiovascular Diseases; Cell Line; Cell Nucleus; Cell Proliferation; Databases, Factual; Diabetes Complications; Diabetes Mellitus, Type 2; Endosonography; Feces; Female; Glomerular Filtration Rate; Glucosides; Glutathione; Humans; Logistic Models; Male; Middle Aged; Ovum; Oxidative Stress; Pancreas; Pancreatic Elastase; Pancreatitis, Chronic; Patient Safety; Predictive Value of Tests; Prevalence; Proportional Hazards Models; Prospective Studies; Prostate; Risk Factors; Schistosoma; Schistosomiasis; Scotland; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Systole; Treatment Outcome | 2017 |
Protective Effects of Salidroside on Lead Acetate-induced Oxidative Stress and Hepatotoxicity in Sprague-Dawley Rats.
Topics: Animals; Antioxidants; Body Weight; Cytochrome P-450 CYP2E1; Female; Glucosides; Humans; Immunohistochemistry; Lead; Liver; NADPH Oxidase 2; Oxidative Stress; Phenols; Rats; Rats, Sprague-Dawley; Temperature | 2019 |
Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
Topics: Appetite; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Eating; Female; Follow-Up Studies; Ghrelin; Glucosides; Glycated Hemoglobin; Glycemic Index; Humans; Leptin; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2019 |
Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Prognosis; Prospective Studies; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2019 |
Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabet
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prognosis; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2019 |
RNA-seq analysis of diet-driven obesity and anti-obesity effects of quercetin glucoside or epigallocatechin gallate in Drosophila adults.
Topics: Animals; Anti-Obesity Agents; Body Weight; Catechin; Diet, High-Fat; Disease Models, Animal; Drosophila; Drug Evaluation, Preclinical; Female; Gene Expression Regulation; Glucosides; Humans; Lipid Metabolism; Male; Metabolomics; Obesity; Oxidative Stress; Quercetin; RNA-Seq; RNA, Messenger; Species Specificity | 2019 |
Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
Topics: Body Weight; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Liver Function Tests; Longitudinal Studies; Male; Middle Aged; Pharmacovigilance; Product Surveillance, Postmarketing; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Effect of Dapagliflozin Treatment on the Expression of Renal Sodium Transporters/Channels on High-Fat Diet Diabetic Mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet, High-Fat; Glucosides; Male; Membrane Transport Proteins; Mice; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Potassium-Exchanging ATPase; Streptozocin | 2019 |
Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2019 |
Cyanidin-3-O-glucoside protects against cadmium-induced dysfunction of sex hormone secretion via the regulation of hypothalamus-pituitary-gonadal axis in male pubertal mice.
Topics: Animals; Anthocyanins; Body Weight; Cadmium; Feeding Behavior; Glucosides; Gonadal Steroid Hormones; Gonads; Hypothalamo-Hypophyseal System; Male; Mice; Sexual Maturation | 2019 |
Rubrofusarin-6-β-gentiobioside inhibits lipid accumulation and weight gain by regulating AMPK/mTOR signaling.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agents; Body Weight; Chromones; Diet, High-Fat; Glucosides; Humans; Lipid Metabolism; Male; Mesenchymal Stem Cells; Mice; Mice, Obese; Obesity; TOR Serine-Threonine Kinases; Weight Gain | 2019 |
Protective Effect of Acteoside on Ovariectomy-Induced Bone Loss in Mice.
Topics: Animals; Biomarkers; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Disease Models, Animal; Female; Glucosides; Mice; Models, Biological; Organ Size; Osteoporosis; Ovariectomy; Phenols; Protective Agents; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; TNF Receptor-Associated Factor 6 | 2019 |
A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
Topics: Adult; Aged; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Republic of Korea; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2019 |
Dynamic Alterations in the Gut Microbiota of Collagen-Induced Arthritis Rats Following the Prolonged Administration of Total Glucosides of Paeony.
Topics: Animals; Ankle Joint; Arthritis, Experimental; Arthritis, Rheumatoid; Bacteria; Body Weight; Collagen; Cytokines; Disease Models, Animal; Drugs, Chinese Herbal; Dysbiosis; Feces; Gastrointestinal Microbiome; Glucosides; Immunity; Immunity, Mucosal; Immunoglobulin A, Secretory; Immunomodulation; Inflammation; Interferon-gamma; Male; Paeonia; Rats; Rats, Sprague-Dawley; Symbiosis; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Th2 Cells; Vascular Endothelial Growth Factor A | 2019 |
Dietary flaxseed protects against ventricular arrhythmias and left ventricular dilation after a myocardial infarction.
Topics: alpha-Linolenic Acid; Animals; Arrhythmias, Cardiac; Body Weight; Butylene Glycols; Cardiotonic Agents; Dietary Supplements; Electrocardiography; Fatty Acids; Flax; Glucosides; Male; Myocardial Infarction; Myocarditis; Organ Size; Rats, Sprague-Dawley; Ventricular Remodeling | 2019 |
Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetic Nephropathies; Diet, High-Protein; Disease Progression; Gene Expression Regulation; Glucosides; Kidney; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2019 |
Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Primary Health Care; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; United Kingdom | 2019 |
Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes.
Topics: Adult; Age Factors; Aged; Benzhydryl Compounds; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome; Young Adult | 2019 |
Creation of resveratrol-enriched rice for the treatment of metabolic syndrome and related diseases.
Topics: Acyltransferases; Adipose Tissue; Animals; Blood Glucose; Body Weight; Chromatography, High Pressure Liquid; Female; Food, Fortified; Glucosides; Glucosyltransferases; Humans; Lipids; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Oryza; Plant Leaves; Plants, Genetically Modified; Resveratrol; Seeds; Sirtuin 1; Stilbenes | 2013 |
Treating type 2 diabetes with canagliflozin.
Topics: Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
Synthesis and biological evaluation of thiophene-C-glucosides as sodium-dependent glucose cotransporter 2 inhibitors.
Topics: Animals; Body Weight; CHO Cells; Cricetinae; Cricetulus; Glucose; Glucosides; Humans; Hypoglycemic Agents; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Structure-Activity Relationship; Thiophenes | 2013 |
Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Exenatide; Glucosides; Glycated Hemoglobin; Hypoglycemic Agents; Male; Mice; Mice, Inbred NOD; Peptides; Venoms | 2014 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Kidney Failure, Chronic; Metformin; Microcirculation; Middle Aged; Myocardial Infarction; Nutrition Surveys; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Uric Acid | 2014 |
Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.
Topics: Animals; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Eating; Glucagon; Glucokinase; Glucose; Glucose Clamp Technique; Glucosides; Hyperglycemia; Hyperinsulinism; Immunohistochemistry; Liver; Male; Obesity; Organ Size; Oxygen Consumption; Rats; Rats, Zucker; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Blood Glucose; Body Weight; Cells, Cultured; Diabetic Nephropathies; Disease Models, Animal; Gene Expression; Glomerular Mesangium; Glucose; Glucosides; Homeostasis; Inflammation; Insulin-Secreting Cells; Kidney; Kidney Cortex; Kidney Function Tests; Kidney Tubules, Proximal; Macrophages; Male; Mice; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Severity of Illness Index; Thiophenes; Treatment Outcome | 2014 |
Polydatin supplementation ameliorates diet-induced development of insulin resistance and hepatic steatosis in rats.
Topics: Adiponectin; Animals; Body Weight; Diet; Dietary Supplements; Disease Models, Animal; Fatty Liver; Gene Expression; Glucose Tolerance Test; Glucosides; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Leptin; Liver; Male; Rats; Stilbenes | 2015 |
Effects of tetrahydroxystilbene glucoside on mouse liver cytochrome P450 enzyme expressions.
Topics: Animals; Body Weight; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Glucosides; Liver; Male; Membrane Proteins; Mice; Organ Size; PPAR alpha; Pregnane X Receptor; Receptors, Aryl Hydrocarbon; Receptors, Steroid; Stilbenes | 2015 |
A combination of glucosyl hesperidin and caffeine exhibits an anti-obesity effect by inhibition of hepatic lipogenesis in mice.
Topics: Adipogenesis; Adipose Tissue; Animals; Anti-Obesity Agents; Body Weight; Caffeine; Diet, High-Fat; Fatty Acid Synthases; Glucosides; Hesperidin; Lipids; Lipogenesis; Liver; Male; Mice; Mice, Obese; Obesity; Sterol Regulatory Element Binding Protein 1 | 2015 |
Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2015 |
Polydatin prevents angiotensin II-induced cardiac hypertrophy and myocardial superoxide generation.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cells, Cultured; Glucosides; Male; Myocardium; Myocytes, Cardiac; NADPH Oxidases; Organ Size; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Resveratrol; RNA, Messenger; Signal Transduction; Stilbenes; Superoxides; Ventricular Myosins | 2015 |
Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Lipids | 2015 |
Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats.
Topics: Amino Acid Transport System ASC; Animals; Body Weight; Carnitine O-Palmitoyltransferase; Cholesterol; Coenzyme A Ligases; Diet, High-Fat; Fenofibrate; Gene Expression Regulation; Glucosides; Humans; Lipid Peroxidation; Lipoproteins, LDL; Liver; Male; Non-alcoholic Fatty Liver Disease; PPAR alpha; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Xanthones | 2015 |
Anthocyanin-rich black elderberry extract improves markers of HDL function and reduces aortic cholesterol in hyperlipidemic mice.
Topics: Alanine Transaminase; Animals; Anthocyanins; Apolipoprotein A-I; Apolipoproteins B; Aryldialkylphosphatase; Aspartate Aminotransferases; Biomarkers; Blood Glucose; Body Weight; Chemokine CCL2; Cholesterol, HDL; Chromatography, High Pressure Liquid; Disaccharides; Disease Models, Animal; Glucosides; Hyperlipidemias; Intestinal Mucosa; Intestines; Male; Mice; Mice, Knockout; Plant Extracts; Sambucus nigra; Thiobarbituric Acid Reactive Substances; Triglycerides | 2015 |
Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Biopsy; Body Weight; Cell Proliferation; Cyclic AMP; Disease Models, Animal; Disease Progression; Diuresis; Electrolytes; Epithelial Cells; Glucosides; Kidney; Kidney Function Tests; Male; Polycystic Kidney Diseases; Rats; Sodium-Glucose Transport Proteins; Ultrasonography | 2015 |
Paeoniflorin Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice.
Topics: Animals; Blood Glucose; Body Weight; Diet, High-Fat; Glucosides; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Monoterpenes; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; Protective Agents; Transcriptome | 2015 |
Catechin-7-O-β-D-glucopyranoside isolated from the seed of Phaseolus calcaratus Roxburgh ameliorates experimental colitis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Catechin; Crohn Disease; Gene Expression Regulation; Glucosides; Glutathione; Male; Malondialdehyde; Mucins; Peroxidase; Phaseolus; Phosphorylation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Seeds; Trinitrobenzenesulfonic Acid | 2015 |
Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Body Composition; Body Weight; Bone Density; Diabetes Mellitus, Experimental; Diet, High-Fat; Energy Metabolism; Fasting; Gastric Inhibitory Polypeptide; Glucosides; Homeostasis; Insulin; Islets of Langerhans; Male; Mice; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
[EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES].
Topics: Belgium; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Product Surveillance, Postmarketing; Surveys and Questionnaires; Thiophenes | 2016 |
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Topics: Adipose Tissue; Adult; Animals; Body Weight; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Epididymis; Glucose; Glucosides; Humans; Hyperphagia; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Renal Insufficiency; Urinary Tract Infections | 2016 |
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
Topics: Animals; Body Weight; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glucosides; Hepatic Stellate Cells; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Cirrhosis, Experimental; Male; Obesity; Organ Size; Rats, Inbred OLETF; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies | 2016 |
Salidroside improves glucose homeostasis in obese mice by repressing inflammation in white adipose tissues and improving leptin sensitivity in hypothalamus.
Topics: Adipose Tissue, White; Animals; Body Weight; Eating; Epididymis; Glucose-6-Phosphatase; Glucosides; Hyperglycemia; Hypothalamus; Inflammation; Leptin; Liver; Male; Mice; Mice, Obese; Obesity; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phenols; Triglycerides | 2016 |
Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice.
Topics: Animals; Body Weight; Cyclic AMP Response Element-Binding Protein; Diabetes Mellitus, Experimental; Diet, Carbohydrate-Restricted; Energy Intake; Fatty Acid Synthases; Forkhead Box Protein O1; Gluconeogenesis; Glucose Tolerance Test; Glucosides; Glycogen; Hyperglycemia; Insulin Resistance; Kidney; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Obesity; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triglycerides; Up-Regulation | 2016 |
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.
Topics: Adipocytes; Adiponectin; Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; C-Reactive Protein; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1 | 2016 |
Polydatin possesses notable anti‑osteoporotic activity via regulation of OPG, RANKL and β‑catenin.
Topics: Alkaline Phosphatase; Animals; beta Catenin; Biomarkers; Body Weight; Bone and Bones; Calcium; Cell Line; Disease Models, Animal; Female; Gene Expression Regulation; Glucosides; Mice; Osteoporosis; Osteoprotegerin; Ovariectomy; RANK Ligand; Stilbenes | 2016 |
Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Diet; Fasting; Glucose Tolerance Test; Glucosides; Inflammasomes; Kidney; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Myocardium; Obesity | 2016 |
The anthocyanin cyanidin-3-O-β-glucoside modulates murine glutathione homeostasis in a manner dependent on genetic background.
Topics: Animals; Anthocyanins; Antioxidants; Body Weight; DNA Damage; Female; Gene Expression Regulation, Enzymologic; Genetic Association Studies; Genetic Background; Glucosides; Glutathione; Glutathione Disulfide; Homeostasis; Mice; Oxidative Stress; Phenotype | 2016 |
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Homeostasis; Humans; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Thiophenes | 2016 |
Visualization of mechanism of action, and a further therapeutic potential of ipragliflozin, a selective SGLT2 inhibitor.
Topics: Adipose Tissue; Animals; Body Weight; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Polymorphism, Single Nucleotide; Sodium-Glucose Transporter 2 | 2017 |
Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cytochrome P-450 CYP2E1; Diet, High-Fat; Disease Models, Animal; Glucosides; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Male; Monoterpenes; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats; Reactive Oxygen Species; Signal Transduction | 2017 |
Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Middle Aged; Primary Health Care; Retrospective Studies | 2017 |
Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits.
Topics: Animals; Body Weight; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Fallopia japonica; Glucosides; Hyperlipidemias; Hypolipidemic Agents; Male; Phytotherapy; Plant Extracts; Plant Roots; Rabbits; Stilbenes; Triglycerides | 2009 |
Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters.
Topics: Animals; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Fallopia japonica; Glucosides; Hyperlipidemias; Hypolipidemic Agents; Male; Mesocricetus; Stilbenes; Triglycerides | 2009 |
Renoprotective effect of total glucosides of paeony (TGP) and its mechanism in experimental diabetes.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Collagen Type I; Creatinine; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucosides; Intercellular Adhesion Molecule-1; Interleukin-1; Kidney; Male; Membrane Proteins; Neurotrophin 3; Paeonia; Phytotherapy; Plant Roots; Rats; Rats, Wistar; Transcription Factor RelA; Transforming Growth Factor beta1; Triglycerides; Tumor Necrosis Factor-alpha | 2009 |
Effects of the flaxseed lignans secoisolariciresinol diglucoside and its aglycone on serum and hepatic lipids in hyperlipidaemic rats.
Topics: Animals; Base Sequence; Body Weight; Butylene Glycols; Dose-Response Relationship, Drug; Female; Flax; Fructose; Gene Expression; Glucosides; Hyperlipidemias; Lignans; Lipids; Liver; Male; Models, Animal; Molecular Sequence Data; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2009 |
Effects of verbascoside biotechnologically produced by Syringa vulgaris plant cell cultures in a rodent model of colitis.
Topics: Animals; Antioxidants; Body Weight; Cells, Cultured; Colitis; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Precursors; Gelatinases; Glucosides; Male; Matrix Metalloproteinase 9; Peroxidase; Phenols; Rats; Rats, Sprague-Dawley; Syringa; Thiobarbituric Acid Reactive Substances; Transcription Factor RelA | 2009 |
Increased CYP4B1 mRNA is associated with the inhibition of dextran sulfate sodium-induced colitis by caffeic acid in mice.
Topics: Alkynes; Animals; Antioxidants; Aryl Hydrocarbon Hydroxylases; Body Weight; Caffeic Acids; Colitis; Colon; Dextran Sulfate; Eating; Female; Gene Expression Regulation, Enzymologic; Glucosides; Humans; Inflammatory Bowel Diseases; Interleukin-17; Interleukin-4; Male; Mice; Nitric Oxide Synthase Type II; Organ Size; Peroxidase; RNA, Messenger; Rutin; Time Factors | 2009 |
Oral supplementation of catalpol ameliorates diabetic encephalopathy in rats.
Topics: Administration, Oral; Animals; Behavior, Animal; Blood Glucose; Body Weight; Catalase; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dietary Supplements; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Glucosides; Glutathione Peroxidase; In Situ Nick-End Labeling; Iridoid Glucosides; Iridoids; Lipid Peroxidation; Male; Malondialdehyde; Maze Learning; Nerve Growth Factor; Oxidative Stress; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Time Factors | 2010 |
Stevioside inhibits atherosclerosis by improving insulin signaling and antioxidant defense in obese insulin-resistant mice.
Topics: Adiponectin; Animals; Antioxidants; Atherosclerosis; Blood Glucose; Body Weight; Diterpenes, Kaurane; Glucosides; Insulin; Insulin Resistance; Mice; Mice, Obese; Obesity; Oxidative Stress; Signal Transduction; Sweetening Agents; Triglycerides | 2010 |
Blood orange juice inhibits fat accumulation in mice.
Topics: Adipose Tissue; Animals; Anthocyanins; Beverages; Body Weight; Citrus sinensis; Dietary Fats; Glucosides; Male; Mice; Mice, Inbred C57BL; Obesity | 2010 |
Resveratrol from transgenic alfalfa for prevention of aberrant crypt foci in mice.
Topics: Animals; Azoxymethane; Body Weight; Chromatography, High Pressure Liquid; Colonic Neoplasms; Eating; Female; Glucosides; Lactase-Phlorizin Hydrolase; Medicago sativa; Mice; Plants, Genetically Modified; Precancerous Conditions; Resveratrol; Stilbenes | 2010 |
Long-term feeding effects of stevioside sweetener on some toxicological parameters of growing male rats.
Topics: Acid Phosphatase; Animals; Biomarkers; Body Weight; Clinical Chemistry Tests; Diterpenes, Kaurane; Dose-Response Relationship, Drug; Glucosides; Hematologic Tests; Isoenzymes; Lipids; Male; Organ Size; Rats; Rats, Sprague-Dawley; Sweetening Agents; Tartrate-Resistant Acid Phosphatase; Toxicity Tests, Chronic | 2011 |
The effect of Eleutheroside E on behavioral alterations in murine sleep deprivation stress model.
Topics: Animals; Antioxidants; Avoidance Learning; Behavior, Animal; Body Weight; Disease Models, Animal; Dopamine; Glucosides; Glutathione; Hippocampus; Lignans; Locomotion; Male; Malondialdehyde; Maze Learning; Mice; Mice, Inbred ICR; Neurotransmitter Agents; Serotonin; Sleep Deprivation; Stress, Psychological; Time Factors | 2011 |
Evaluation of dietary stevioside supplementation on anti-human serum albumin immunoglobulin G, Alpha-1-glycoprotein, body weight and thyroid hormones in broiler chickens.
Topics: Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Body Weight; Chickens; Diet; Dietary Supplements; Diterpenes, Kaurane; Enzyme-Linked Immunosorbent Assay; Glucosides; Humans; Immunoglobulin G; Male; Serum Albumin; Sweetening Agents; Thyroxine; Triiodothyronine | 2012 |
Subchronic toxicity evaluation of aloesin.
Topics: Administration, Oral; Animals; Body Weight; Chromones; Dose-Response Relationship, Drug; Drinking; Eating; Eye; Female; Glucosides; Ketones; Male; No-Observed-Adverse-Effect Level; Organ Size; Rats; Rats, Sprague-Dawley; Weight Gain | 2011 |
A naturally occurring naringenin derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts.
Topics: Anabolic Agents; Animals; Biological Availability; Body Weight; Bone Diseases, Metabolic; Bone Morphogenetic Proteins; Cell Differentiation; Estrogens; Female; Flavanones; Flavonoids; Glucosides; Male; Mice; Mice, Inbred BALB C; Osteoblasts; Osteogenesis; Ovariectomy; Parathyroid Hormone; Phloretin; Rats; Rats, Wistar; Receptors, Estrogen; Skull | 2012 |
Protective effect of salidroside from Rhodiolae Radix on diabetes-induced oxidative stress in mice.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Fasting; Glucosides; Insulin; Kidney; Lipids; Liver; Male; Malondialdehyde; Mice; Oxidative Stress; Phenols; Protective Agents; Rhodiola | 2011 |
Comparative effects of sesame seed lignan and flaxseed lignan in reducing the growth of human breast tumors (MCF-7) at high levels of circulating estrogen in athymic mice.
Topics: Animals; Apoptosis; Body Weight; Breast Neoplasms; Butylene Glycols; Cell Line, Tumor; Cell Proliferation; Dioxoles; Eating; Estrogens; Female; Flax; Glucosides; Humans; Lignans; Mice; Mice, Nude; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Seeds; Sesamum; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
IGF-1 induction by acylated steryl β-glucosides found in a pre-germinated brown rice diet reduces oxidative stress in streptozotocin-induced diabetes.
Topics: Acylation; Animals; Apoptosis; Blood Glucose; Body Weight; Cell Survival; Culture Media; Diabetes Mellitus, Experimental; Diet; Gene Expression Regulation; Germination; Glucose; Glucosephosphate Dehydrogenase; Glucosides; Glycolysis; Insulin; Insulin-Like Growth Factor I; Male; Models, Biological; Oryza; Oxidative Stress; Pentose Phosphate Pathway; Rats; Rats, Wistar; Reactive Oxygen Species; RNA, Messenger | 2011 |
Preventive effects of hesperidin, glucosyl hesperidin and naringin on hypertension and cerebral thrombosis in stroke-prone spontaneously hypertensive rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Body Weight; Deoxyguanosine; Flavanones; Glucosides; Hesperidin; Hypertension; Intracranial Thrombosis; Male; Nitric Oxide; Oxidative Stress; Rats; Rats, Inbred SHR; Vasodilation | 2012 |
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
Topics: Animals; Blood Glucose; Body Weight; Canagliflozin; Cells, Cultured; CHO Cells; Cricetinae; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Glucosides; Humans; Hyperglycemia; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle, Skeletal; Rats; Rats, Zucker; Sodium-Glucose Transport Proteins; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Gain | 2012 |
[Experimental studies on toxic effects of Tiangou Jiangya capsule].
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzyl Alcohols; Body Weight; Drugs, Chinese Herbal; Eating; Electrocardiography; Female; Flavonoids; Furans; Glucosides; Lignans; Male; Mice; Mice, Inbred ICR; Rats; Rats, Wistar | 2011 |
Potential effects of lignan-enriched flaxseed powder on bodyweight, visceral fat, lipid profile, and blood pressure in rats.
Topics: Animals; Blood Pressure; Body Weight; Butylene Glycols; Diet, High-Fat; Dietary Fats; Dietary Sucrose; Flax; Food, Fortified; Fructose; Glucosides; Heart; Intra-Abdominal Fat; Kidney; Leptin; Lipids; Liver; Male; Organ Size; Rats; Rats, Sprague-Dawley; Seeds | 2012 |
[D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
Topics: Administration, Oral; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Drug Combinations; Drug Synergism; Eating; Energy Metabolism; Exenatide; Glucosides; Hypoglycemic Agents; Insulin; Insulin Resistance; Islet Amyloid Polypeptide; Leptin; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Peptide Fragments; Peptides; Venoms | 2012 |
Polydatin ameliorates renal injury by attenuating oxidative stress-related inflammatory responses in fructose-induced urate nephropathic mice.
Topics: Animals; Blood Chemical Analysis; Body Weight; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Drugs, Chinese Herbal; Fructose; Glucosides; Inflammation; Interleukin-1beta; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred Strains; NF-kappa B; Nitric Oxide Synthase Type II; Oxidative Stress; Protective Agents; Stilbenes; Tumor Necrosis Factor-alpha; Uric Acid; Xanthine Oxidase | 2013 |
Effect of sprout extract from Tuscan black cabbage on xenobiotic-metabolizing and antioxidant enzymes in rat liver.
Topics: Animals; Anticarcinogenic Agents; Antioxidants; Benzoates; Body Weight; Brassica; Cytochrome P-450 Enzyme System; Glucosides; Glycoside Hydrolases; Isothiocyanates; Liver; Male; Metabolic Detoxication, Phase II; Organ Size; Plant Extracts; Rats; Rats, Sprague-Dawley; Xenobiotics | 2013 |
Protective effect of colored rice over white rice on Fenton reaction-based renal lipid peroxidation in rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Anthocyanins; Body Weight; Carcinogens; Catalase; Deoxyguanosine; Diet; Ferric Compounds; Glucosides; Glutathione Peroxidase; Glutathione Transferase; Hydrogen Peroxide; Hydroxybenzoates; Immunoenzyme Techniques; Iron; Kidney Diseases; Kidney Tubules, Proximal; Lipid Peroxidation; Male; Nitrilotriacetic Acid; Oryza; Phytotherapy; Rats; Rats, Wistar; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2002 |
Antihyperglycemic and blood pressure-reducing effects of stevioside in the diabetic Goto-Kakizaki rat.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Cell Line; Diabetes Mellitus, Type 2; Diterpenes; Diterpenes, Kaurane; Fasting; Gene Expression Profiling; Glucagon; Glucose Tolerance Test; Glucosides; Hypoglycemic Agents; Insulin; Islets of Langerhans; Kinetics; Male; Rats; Rats, Wistar | 2003 |
Acarviosine-simmondsin, a novel compound obtained from acarviosine-glucose and simmondsin by Thermus maltogenic amylase and its in vivo effect on food intake and hyperglycemia.
Topics: Acetonitriles; alpha-Amylases; Amino Sugars; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Carbohydrate Sequence; Cyclohexanes; Eating; Glucose; Glucosides; Glycoside Hydrolase Inhibitors; Glycoside Hydrolases; Glycosylation; Hydrolysis; Hyperglycemia; Hypoglycemic Agents; Molecular Sequence Data; Postprandial Period; Rats; Rats, Sprague-Dawley; Swine; Thermus | 2003 |
Dietary cyanidin 3-O-beta-D-glucoside-rich purple corn color prevents obesity and ameliorates hyperglycemia in mice.
Topics: Adipose Tissue; Animals; Anthocyanins; Base Sequence; Body Weight; CCAAT-Enhancer-Binding Proteins; Diet; DNA Primers; DNA-Binding Proteins; Energy Intake; Glucosides; Hyperglycemia; Insulin Resistance; Lipids; Liver; Male; Mice; Mice, Inbred BALB C; Obesity; Organ Size; Sterol Regulatory Element Binding Protein 1; Transcription Factors | 2003 |
Exposure to flaxseed or its purified lignan during suckling inhibits chemically induced rat mammary tumorigenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Animals, Suckling; Body Weight; Butylene Glycols; Carcinogens; Diet; Disease Models, Animal; Female; Flax; Glucosides; Lactation; Lignans; Mammary Neoplasms, Experimental; Rats; Rats, Sprague-Dawley; Reproduction | 2003 |
Phytochemical studies and effect on urine volume of Glossostemon bruguieri Desf. constituents.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Creatinine; Flavonoids; Glucosides; Kidney; Liver Function Tests; Plant Extracts; Plants, Medicinal; Quercetin; Rats; Urea; Uric Acid; Urine | 2004 |
Effects of forsythia fruit extracts and lignan on lipid metabolism.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Cell Line, Tumor; Cholesterol, Dietary; Dietary Supplements; Forsythia; Furans; Glucosides; Humans; Lignans; Lipid Metabolism; Lipids; Male; Plant Extracts; Rats; Rats, Sprague-Dawley; Seeds | 2004 |
Ethyl alpha-D-glucoside was absorbed in small intestine and excreted in urine as intact form.
Topics: Analysis of Variance; Animals; Blood Glucose; Body Weight; Chromatography, High Pressure Liquid; Drinking; Food; Glucosides; In Vitro Techniques; Insulin; Intestinal Absorption; Intestine, Small; Maltose; Rats; Rats, Wistar | 2005 |
Effects of aloe, aloesin, or propolis on the pharmacokinetics of benzo[a]pyrene and 3-OH-benzo[a]pyrene in rats.
Topics: Aloe; Animals; Benzo(a)pyrene; Benzopyrenes; Bile; Body Weight; Chromatography, High Pressure Liquid; Chromones; Feces; Glucosides; Male; Plant Extracts; Propolis; Rats; Rats, Sprague-Dawley; Urine | 2005 |
Simmondsin for weight loss in rats.
Topics: Acetonitriles; Animals; Appetite Depressants; Body Composition; Body Weight; Cyclohexanes; Dose-Response Relationship, Drug; Eating; Erythrocytes; Glucosides; Kidney; Leukocytes; Liver; Male; Obesity; Organ Size; Rats; Rats, Sprague-Dawley; Thinness; Weight Loss | 2006 |
Effects of four Si-Wu-Tang's constituents and their combination on irradiated mice.
Topics: Animals; Benzoates; Body Weight; Bone Marrow Cells; Bridged-Ring Compounds; Colony-Forming Units Assay; Coumaric Acids; Disease Models, Animal; Dose-Response Relationship, Radiation; Drugs, Chinese Herbal; Female; Fructose; Gamma Rays; Glucosides; Hematopoietic Stem Cells; Mice; Mice, Inbred C57BL; Monoterpenes; Pyrazines; Radiation-Protective Agents; Stem Cells; Thymus Gland | 2006 |
Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism.
Topics: Animals; Antioxidants; Aorta; Atherosclerosis; Body Weight; Butylene Glycols; Cholesterol, Dietary; Female; Glucosides; Hypercholesterolemia; Lipids; Luminescence; Malondialdehyde; Pentoxifylline; Rabbits | 2007 |
Investigations on the effects of alkyl polyglucosides on development and fertility.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Fertility; Fetal Development; Genes, Reporter; Glucosides; Humans; Luciferases; Male; No-Observed-Adverse-Effect Level; Pregnancy; Random Allocation; Rats; Rats, Sprague-Dawley; Surface-Active Agents | 2007 |
Feeding flaxseed oil but not secoisolariciresinol diglucoside results in higher bone mass in healthy rats and rats with kidney disease.
Topics: Animals; Body Weight; Bone Density; Butylene Glycols; Corn Oil; Dietary Fats; Female; Glucosides; Kidney Diseases; Linseed Oil; Male; Random Allocation; Rats; Rats, Inbred Strains | 2007 |
Assay of cardiac glucosides by the guinea-pig method; influence of sex and weight.
Topics: Biological Assay; Body Weight; Glucosides; Guinea Pigs; Heart; Humans | 1949 |
Isolation of factors in linseed oil meal protective against chronic selenosis in rats.
Topics: Amygdalin; Animals; Body Weight; Chronic Disease; Glucosides; Glycosides; Kidney; Liver; Male; Nitriles; Oils; Organ Size; Poisoning; Rats; Selenium | 1980 |
Influence of long-term simmondsin administration on thyroid hormone levels in adult rats.
Topics: Acetonitriles; Animals; Body Weight; Circadian Rhythm; Cyclohexanes; Eating; Glucosides; Iodide Peroxidase; Liver; Male; Rats; Rats, Wistar; Thyroid Hormones; Weight Gain | 1995 |
Effects of orally administered liposomes with soybean-derived sterols and their glucosides on rat body weight.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Administration, Oral; Animals; Body Weight; Drug Carriers; Erythropoietin; Glucosides; Glycine max; Injections, Subcutaneous; Lipids; Liposomes; Male; Phytosterols; Rats; Rats, Wistar | 1995 |
The influence of flaxseed and lignans on colon carcinogenesis and beta-glucuronidase activity.
Topics: Animals; Anticarcinogenic Agents; Body Weight; Butylene Glycols; Cecum; Colonic Neoplasms; Eating; Fatty Acids; Glucosides; Glucuronidase; Hydrogen-Ion Concentration; Lignans; Male; Organ Size; Plant Extracts; Precancerous Conditions; Rats; Rats, Sprague-Dawley; Seeds | 1996 |
Antihyperglycemic activity of phenolics from Pterocarpus marsupium.
Topics: Animals; Benzofurans; Blood Glucose; Body Weight; Cresols; Diabetes Mellitus, Experimental; Female; Glucosides; Hypoglycemic Agents; Male; Metformin; Phenols; Plants, Medicinal; Rats; Stilbenes; Wood | 1997 |
Assessment of the carcinogenicity of stevioside in F344 rats.
Topics: Administration, Oral; Animals; Body Weight; Carcinogenicity Tests; Diterpenes; Diterpenes, Kaurane; Eating; Female; Glucosides; Kidney Diseases; Male; Neoplasms, Experimental; Organ Size; Rats; Rats, Inbred F344; Survival Rate; Sweetening Agents; Terpenes | 1997 |
The promoting effects of geniposidic acid and aucubin in Eucommia ulmoides Oliver leaves on collagen synthesis.
Topics: Aging; Animals; Body Weight; Collagen; Drugs, Chinese Herbal; Glucosides; Granuloma; Iridoid Glucosides; Iridoids; Magnoliopsida; Male; Organ Size; Plant Leaves; Pyrans; Rats; Rats, Wistar | 1998 |
Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed.
Topics: Animals; Aortic Diseases; Arteriosclerosis; Body Weight; Butylene Glycols; Cholesterol; Cholesterol, LDL; Diet, Atherogenic; Glucosides; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins; Luminescent Measurements; Malondialdehyde; Rabbits; Seeds; Triglycerides | 1999 |
Improvement in the turnover rate of the stratum corneum in false aged model rats by the administration of geniposidic acid in Eucommia ulmoides Oliver Leaf.
Topics: Aging; Animals; Body Weight; Drugs, Chinese Herbal; Epidermis; Glucosides; Iridoid Glucosides; Iridoids; Male; Plant Extracts; Plants, Medicinal; Pyrans; Rats; Rats, Wistar | 1999 |
Effects of simmondsin on food intake, growth, and metabolic variables in lean (+/?) and obese (fa/fa) Zucker rats.
Topics: Acetonitriles; Adipose Tissue; Animals; Appetite Depressants; Body Temperature Regulation; Body Weight; Cholesterol; Cyclohexanes; Eating; Glucosides; Growth; Leptin; Male; Obesity; Proteins; Rats; Rats, Zucker; Time Factors | 1999 |
Hyperglycemia impairs the insulin signaling step between PI 3-kinase and Akt/PKB activations in ZDF rat liver.
Topics: Animals; Blood Glucose; Body Weight; Carbonates; Dose-Response Relationship, Drug; Enzyme Activation; Glucosides; Hyperglycemia; Insulin; Insulin Receptor Substrate Proteins; Intracellular Signaling Peptides and Proteins; Liver; Membrane Glycoproteins; Monosaccharide Transport Proteins; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Zucker; Receptor, Insulin; Signal Transduction; Sodium-Glucose Transporter 1; Time Factors | 1999 |
In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Breast Neoplasms; Carbazoles; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Glucosides; Humans; Indoles; Leukemia P388; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Mice, Nude; Neoplasms; Paclitaxel; Prostatic Neoplasms; Time Factors | 1999 |
Lack of carcinogenicity of gardenia blue colour given chronically in the diet to F344 rats.
Topics: Administration, Oral; Animals; Blood; Body Weight; Carcinogenicity Tests; Dose-Response Relationship, Drug; Female; Glucosides; Iridoids; Male; Neoplasms, Experimental; Organ Size; Plant Extracts; Pyrans; Rats; Rats, Inbred F344; Survival Rate | 2000 |
The vagus nerve is involved in the anorexigenic effect of simmondsin in the rat.
Topics: Acetonitriles; Analysis of Variance; Animals; Anorexia; Appetite Depressants; Body Weight; Cyclohexanes; Eating; Fasting; Glucosides; Male; Nootropic Agents; Rats; Rats, Wistar; Sincalide; Vagotomy; Vagus Nerve | 2000 |
Effects of arctiin on PhIP-induced mammary, colon and pancreatic carcinogenesis in female Sprague-Dawley rats and MeIQx-induced hepatocarcinogenesis in male F344 rats.
Topics: Animals; Biological Assay; Body Weight; Carcinogens; Carcinoma; Colonic Neoplasms; Diet; Drugs, Chinese Herbal; Female; Fibroadenoma; Furans; Glucosides; Glutathione Transferase; Imidazoles; Liver; Male; Mammary Neoplasms, Experimental; Pancreatic Neoplasms; Quinoxalines; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Time Factors | 2000 |
T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats.
Topics: Albuminuria; Animals; Blood Glucose; Body Weight; Carbonates; Diabetes Mellitus, Experimental; Glucose Transporter Type 2; Glucosides; Glycated Hemoglobin; Glycosuria; Hyperglycemia; Hypoglycemic Agents; Jejunum; Kidney; Male; Monosaccharide Transport Proteins; Organ Size; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Urine | 2000 |
Plasma insulin-like growth factor I levels in rats are reduced by dietary supplementation of flaxseed or its lignan secoisolariciresinol diglycoside.
Topics: Animals; Anticarcinogenic Agents; Body Weight; Butylene Glycols; Carcinogens; Dietary Supplements; Eating; Female; Flax; Glucosides; Insulin-Like Growth Factor I; Lignans; Mammary Glands, Animal; Methylnitrosourea; Organ Size; Rats; Rats, Sprague-Dawley | 2000 |
Pronounced inhibition by a natural anthocyanin, purple corn color, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-associated colorectal carcinogenesis in male F344 rats pretreated with 1,2-dimethylhydrazine.
Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Adenocarcinoma, Mucinous; Adenoma; Administration, Oral; Animals; Anthocyanins; Anticarcinogenic Agents; Body Weight; Carcinogens; Cocarcinogenesis; Colonic Diseases; Colorectal Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; Glucosides; Hyperplasia; Imidazoles; Intestinal Mucosa; Jejunal Neoplasms; Male; Precancerous Conditions; Prostatic Neoplasms; Rats; Rats, Inbred F344; Seminal Vesicles; Zea mays | 2001 |
Physiological and biochemical changes associated with linamarin administration to rats.
Topics: Animals; Blood Pressure; Body Weight; Cyanides; Eating; Electrocardiography; Electron Transport Complex IV; Glucosides; Glycosides; Lactates; Male; Manihot; Myocardium; Nitriles; Pyruvates; Rats; Respiration; Thiocyanates | 1977 |
"Luminal nutrition" versus "functional work-load" as controllers of mucosal morphology and epithelial replacement in the rat small intestine.
Topics: Animals; Body Weight; Epithelial Cells; Epithelium; Galactose; Glucose; Glucosides; Intestinal Mucosa; Intestine, Small; Male; Rats; Sodium Chloride; Vincristine | 1977 |
Studies with chicks on the growth depressing factor(s) in faba beans (Vicia faba L. var. minor).
Topics: Animals; Body Weight; Chickens; Diet; Glucosides; Growth; Hot Temperature; Liver; Male; Organ Size; Pancreas; Spleen; Vegetables | 1976 |
[Subchronic oral toxicity study of stevioside in F344 rats].
Topics: Administration, Oral; Animals; Body Weight; Diterpenes; Diterpenes, Kaurane; Female; Glucosides; Hematologic Tests; Male; Organ Size; Rats; Rats, Inbred F344; Terpenes; Time Factors | 1991 |
Chronic oral toxicity and carcinogenicity study of stevioside in rats.
Topics: Animals; Body Weight; Carcinogens; Diterpenes; Diterpenes, Kaurane; Eating; Female; Glucosides; Lung; Male; Neoplasms, Experimental; Organ Size; Rats; Rats, Wistar; Sweetening Agents; Terpenes; Time Factors | 1992 |
Incomplete utilization of pyridoxine-beta-glucoside as vitamin B-6 in the rat.
Topics: Administration, Oral; Animals; Aspartate Aminotransferases; Biological Availability; Body Weight; Erythrocytes; Glucosides; Male; Pyridoxine; Rats; Rats, Inbred Strains | 1988 |